BMJ Open

The efficacy of sodium bicarbonate preventing contrastinduced nephropathy in patients with preexisting renal insufficiency: a meta-analysis

Journal:	BMJ Open				
Manuscript ID:	bmjopen-2014-006989				
Article Type:	Research				
Date Submitted by the Author:	23-Oct-2014				
Complete List of Authors:	Zhang, Bin; 1.Southern Medical University;2.Guangdong General Hospital, Radiology Liang, Long; 1.Southern Medical University;2.Guangdong General Hospital, Radiology Chen, WB; Guangdong General Hospital, Radiology Liang, CH; Guangdong General Hospital, Radiology Zhang, SX; Guangdong General Hospital, Radiology				
Primary Subject Heading :	Radiology and imaging				
Secondary Subject Heading:	Global health, Renal medicine, Public health, Evidence based practice				
Keywords:	Dialysis < NEPHROLOGY, Chronic renal failure < NEPHROLOGY, Acute renal failure < NEPHROLOGY				
Note: The following files were submitted by the author for peer review, but cannot be converted to PDF. You must view these files (e.g. movies) online.					

figures.rar

SCHOLARONE[™] Manuscripts

BMJ Open

The efficacy of sodium bicarbonate preventing contrast-induced
nephropathy in patients with preexisting renal insufficiency: a
meta-analysis
Bin Zhang ^{1,2} , Long Liang ^{1,2} , Wenbo Chen ² , Changhong Liang ² , Shuixing Zhang ² .
1Graduate College, Southern Medical University, 510515 Guangzhou, China
2Department of Radiology, Guangdong Academy of Medical Sciences/Guangdong
Constal Haspital No. 106 Zhangshan Er Doad, E10080 Cuangzhou, Cuangdong Drov
General Hospital, No. 106 Zhongshan Er Road, 510080 Guangzhou, Guangdong Prov,
People's Republic of China
Corresponding author: Shuixing Zhang, Department of Radiology, Guangdong
Academy of Medical Sciences/Guangdong General Hospital, No. 106 Zhongshan Er
Road, 510080 Guangzhou, Guangdong Prov, People's Republic of China
E-mail: shui7515@hotmail.com
Tel: +86 20 83870125 Fax: +86 20 83870125
Key words: Sodium bicarbonate; Saline; Contrast-induced nephropathy;
Renal insufficiency; Meta-analysis
Test word source 2004
Text word count:2884

BMJ Open: first published as 10.1136/bmjopen-2014-006989 on 17 March 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) .

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

ABSTRACT

Objective: The primary objective of this meta-analysis was to explore the efficacy of sodium bicarbonate in preventing contrast-induced nephropathy (CIN) and assess if it could reduce the risks of dialysis and mortality, thus improving the clinical prognosis of patients with CIN.

Methods: A comprehensive literature search of PubMed, Medline and Cochrane Library was conducted through August 2014.The effect estimate was expressed as pooled odds ratio(OR) with 95% confidence interval(CI), using the random-effects model.

Results: A total of 20 clinical trials consisting of 4,280 patients were absorbed into this study. Pre-procedural hydration with sodium bicarbonate was associated with a significant decrease in the incidence of CIN among patients with preexisting renal insufficiency(OR 0.67; 95%CI 0.47-0.96; P=0.027).However, moderate heterogeneity was noted among the included trials(1²=48%;P=0.008).Therefore, we performed subgroup analyses and indicated a more pronounced effect of sodium bicarbonate in studies using low-osmolar contrast agents(OR 0.59; 95%CI: 0.37-0.93,P=0.024) compared with those using iso-osmolar ones(OR 0.76; 95%CI: 0.43-1.34,P=0.351). Similarly,a lower odds of CIN with sodium bicarbonate occurred in studies including

exclusively patients undergoing emergency procedures (OR 0.16; 95%CI: 0.05-0.51, P=0.002)compared with those undergoing elective ones (OR 0.76;95%CI:0.54-1.06,

P=0.105). Furthermore, sodium bicarbonate played a more active role in patients given bolus injection before procedures (OR 0.15; 95%CI: 0.04-0.54, P=0.004) compared with continuous infusion(OR 0.75; 95%CI:0.53-1.05,P=0.091).

Sodium bicarbonate plus N-acetylcysteine (NAC) (OR 0.17; 95%CI:0.04-0.79,P=0.024) outweighed sodium bicarbonate alone (OR 0.71;95%CI:0.48-1.03,P=0.071).The effect of sodium bicarbonate was considered greater in papers published before 2008(OR 0.19;95%CI:0.09-0.41,P=0.000) than after 2008(OR 0.85; 95%CI: 0.62-1.16, P=0.302).

However, no significant difference was found in the mortality (OR 0.69;95%CI:0.36-1.32,P=0.263)and need for dialysis(OR 1.08;95%CI:0.52-2.25,P=0.841).

Conclusions: Sodium bicarbonate is effective in preventing CIN among patients with preexisting renal insufficiency. However, it failures to lower the risks of dialysis and mortality and thus cannot improve the clinical prognosis of patients with CIN.

Article summary

Article focus:

• To explore the efficacy of sodium bicarbonate in preventing contrast-induced nephropathy.

• To assess if sodium bicarbonate could reduce the risks of dialysis and mortality, thus improving the clinical prognosis of patients with CIN.

Key messages:

• Sodium bicarbonate is effective in preventing CIN among patients with preexisting renal insufficiency.

• Infusion of sodium bicarbonate failures to lower the risks of dialysis and mortality.

BMJ Open: first published as 10.1136/bmjopen-2014-006989 on 17 March 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) .

text

data mining, Al training, and similar technologies

Protected by copyright, including for uses related to

Strengths and limitations of this study

• In this updated meta-analysis, we demonstrate that pre-procedural hydration with sodium bicarbonate is associated with a significant decrease in the incidence of CIN among patients with preexisting renal insufficiency.

• In this study, we find that sodium bicarbonate failures to lower the risks of dialysis and mortality and thus cannot improve the clinical prognosis of patients with CIN.

- New Jadad Scale after revision was used to assess the quality of articles.
- No publication bias.
- However, moderate heterogeneity was noted among the included trials.

Keywords: Sodium bicarbonate; Saline; Contrast-induced nephropathy;

Renal insufficiency; Meta-analysis

Introduction

BMJ Open: first published as 10.1136/bmjopen-2014-006989 on 17 March 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES)

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

Contrast-induced nephropathy is the third leading cause of in-hospital acute kidney injury[1-3], which is a serious complication of angiographic procedures resulting from the administration of contrast media. Although the definition of CIN is various, CIN is usually defined as an increase in serum creatinine level of 25% or an increase of 0.5mg/dl (or 44µmol/L) from baseline within 48-72h of contrast exposure. It results in increased morbidity, prolonged hospital stay, and increased healthcare expenditure and is associated with a higher mortality[4].

The incidence of CIN in the general population is low, but increases exponentially in patients with high-risk factors, such as preexisting renal insufficiency, diabetes mellitus[5]. In a recent study, 21.7% of preexisting chronic renal insufficiency group and 6.3% of no preexisting chronic renal insufficiency group developed CIN[6]. Thus, baseline renal insufficiency was a significant predisposing factor of CIN.

To prevent CIN, sodium bicarbonate-based hydration has been proposed as one of the feasible therapies. According to recent studies, some of them suggested that for prevention of CIN, sodium bicarbonate elicited more protective effect compared with sodium chloride, but others did not [7-17]. Although most previous meta analyses were on the side of sodium bicarbonate with possible publication bias, none of them focused on the patients with preexisting renal insufficiency. Therefore, we performed this meta-analysis to test the efficacy of sodium bicarbonate in preventing of contrast-induced nephropathy among patients with renal insufficiency undergoing various procedures that need contrast agents. What's more, differences in need for dialysis and post-procedural death between two arms were also compared in this study.

Methods

Data Sources and Searches

We searched PubMed, Medline, Cochrane Library from 2004 through to 1 August 2014. Medical subject headings and keyword searches included the terms "contrast

induced nephropathy", "sodium bicarbonate", "sodium chloride", "saline", "acute kidney injury", "renal failure". Reference lists of selected articles were reviewed for other potentially relevant citations. In addition, top 50 citations for each identified relevant study were searched by using the "related articles" function of PubMed.

Study Selection

Firstly, two investigators(B.Z and L.L) independently reviewed the titles and abstracts of all studies searched to identify all potentially relevant ones. Secondly, the online publications obtained from preliminary selection were reviewed in full text by the same two investigators to assess if studies met the following inclusion criteria: comparison of sodium bicarbonate versus sodium chloride or saline, RCT, age \geq 18 years, clinical end point assessment included CIN, patients with preexisting renal insufficiency: defined as a serum creatinine concentration of >1.1 mg/dl or estimated glomerular filtration rate(eGFR)<60ml/min[18]or creatinine clearance rate<60ml/min [9]. Reviewers were not blinded to study authors or outcomes. Final inclusion of studies was based on the agreement of both reviewers.

Data Extraction and Quality Assessment

Two reviewers(B.Z and WB.C) extracted relevant information from the literatures including baseline clinical characteristics(mean age, the percentage of males, risk factors other than renal insufficiency, baseline Scr, eGFR, procedures, interventions, type and volume of contrast media , hydration regimen, definition of CIN)(Tab1) and data on primary(the incidence of CIN) and secondary outcomes, such as need for dialysis, mortality. CIN was defined variously in studies, but most of them described it as a absolute or relative increase in the level of serum creatinine. Three studies defined CIN as a rise in serum creatinine by 25% or more within 2-5d of contrast exposure [12,19,20]. Thirteen studies regarded an increase of 0.5mg/dl or 25% in Scr within 2-4d of contrast. Two studies considered a elevated Scr of 0.5mg/dl after the procedures[9, 15]. However, two other trials presented were different from all above,

BMJ Open: first published as 10.1136/bmjopen-2014-006989 on 17 March 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES)

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

a decrease in eGFR of 25% within 4d and an absolute increase in Scr of at least 0.3mg/dl or 50% or Urine output<0.5ml·kg⁻¹·h⁻¹(>6h) within 5d were selected to define CIN, respectively[8,17]. We assessed the quality of articles using New Jadad

Data Synthesis and Analysis

Scale after revision(Tab 2).

The data from included studies were combined and expressed as pooled OR with 95%CI. All analyses were performed on an "intention-to-treat" basis. Initially, fixed -effects model (Mantel-Haenzel method) was used in this meta-analysis. We evaluated the heterogeneity across studies with the Q and I² statistics. If P value<0.1, statistically significant heterogeneity was considered. The I² statistic was used to quantify the magnitude of heterogeneity, with values of 0-30%,31-50% and greater than 50% representing mild, moderate and substantial heterogeneity, respectively. The outcome of fixed-effects model analysis demonstrated a statistical heterogeneity, so we selected random-effects model (Dersimonian and Laird method).

Considering of the clinical and statistical heterogeneity across studies, subgroup analyses were performed to assess the effect of sodium bicarbonate in various conditions, such as low-osmolar vs.iso-osmolar contrast agent, emergency vs.elective procedures, article published before vs. after 2008, and continuous vs.bolus infusion of sodium bicarbonate (Tab 3). An influence analysis was carried out to evaluate how robust the pooled estimator is after removal of individual studies(Fig 4). An individual study is suspected of excessive influence if the point estimate of its omitted analysis lies outside the 95%CI of the summary analysis.Publication bias was assessed using Begg' funnel plot and Egger' regression asymmetry test(Fig 5). All statistical analyses were conducted using STATA software, version 12.0(Stata Corp LP,College Station, Texas).

Results

A total of 837 articles were reviewed and 20 studies met the inclusion criteria were absorbed into this study finally(Fig 1).

A detailed description of the baseline characteristics of the included studies is given in Tab 1. Patients in most studies underwent coronary angiography or Interventional procedures. There were also seven studies depicted peripheral procedures, angioplasty, cardiopulmonary bypass and CT[8,18,19,21-24]. The sodium bicarbonate hydration regimen in thirteen studies was described as same as Merten et al: the infusion of sodium bicarbonate at rate of 3ml·kg⁻¹·h⁻¹ for 1h before and 1ml·kg⁻¹·h⁻¹ for 6h after the procedure.

Primary Outcome

CIN occurred in a total of 158 patients in the 2,130 patients of the sodium bicarbonate arm compared with that of 217 patients in the 2,150 patients who received saline, a lower overall incidence of CIN was found in the sodium bicarbonate group(Fig 2). The pooled OR was 0.67 (95%CI:0.47-0.96; P=0.027) also in favor of sodium bicarbonate(Fig 2).

However, moderate heterogeneity across studies was observed(I²=48%,P=0.008) (Fig 2).

Therefore, subgroup analyses were constructed and suggested a more pronounced effect of sodium bicarbonate in studies using low-osmolar contrast media(OR 0.59; 95%CI: 0.37-0.93,P=0.024) (Tab 3). Similarly, subgroup analysis by the setting suggested lower odds of CIN with sodium bicarbonate in studies with patients undergoing emergency procedures (OR 0.16; 95%CI 0.05-0.51, P=0.002) (Tab 3). Before 2008, the effect of sodium bicarbonate was considered greater in articles reported(OR 0.19;95%CI:0.09-0.41,P=0.000)(Tab 3). Furthermore, subgroup analysis according to the manner of sodium bicarbonate administration showed better effect in patients given bolus injection (OR 0.15; 95%CI 0.04-0.54, P=0.004) (Tab 3).Sodium bicarbonate in combination with NAC showed a more salient efficacy in preventing

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

CIN(OR 0.17;95%CI:0.04-0.79,P=0.024)(Tab 3).

Influence analysis showed no individual study had excessive influence on the overall estimate odds ratios and 95%CI(Fig 4).

Begg' funnel plot and Egger' test(P=0.396) implied no significant publication bias in this study(Fig 5).

Secondary Endpoints

Need for dialysis

The need for dialysis was described in a total of 17 studies(n=3,633). In eight of these studies, there was no dialysis event in both groups[11,12,15,16,18,19,22,24]. Overall, 14 out of 1,809 patients who treated with sodium bicarbonate underwent dialysis compared with 13 out of 1,824 patients treated with saline. No statistical significant difference was observed (OR 1.08; 95%CI 0.52-2.25, P=0.841) (Fig 3a), nonetheless, the OR for the requirement of dialysis suggested that maybe sodium bicarbonate was no better than saline in terms of reducing the dialysis events.

Mortality

Post-procedural death was described in a total of 12 studies(n=2,559), in six studies, there was no death in either group[11,13,14,16,23,24]. There were altogether 15 deaths in the 1,279 patients treated with sodium bicarbonate and 22 in the 1,280 patients treated with saline. Although there was no significant difference between the two arms (OR 0.69; 95%CI 0.36-1.32, P=0.263) (Fig 3b), a trend toward lower mortality risk occurred in sodium bicarbonate arm compared with saline arm.

Discussion

Although CIN is generally regarded as a transient decline in renal function after contrast procedures, it cannot be regarded as a benign complication[25,26]. It accounts for 12% of all cases of acute renal failure[27]. In a observational study, 0.8% of included patients undergoing coronary angiography or Interventional procedures started dialysis and 13% of them needed a permanent one[28]. Furthermore, the

development of CIN is associated with a longer hospital stay, an increased morbidity and mortality, in addition to a higher financial cost. Consequently, we can never be blind to the hazard of CIN.

Various risk factors may contribute to CIN, which are divided into two groups: patient- and procedure-related[29]. Preexisting renal insufficiency and diabetes mellitus are the two main patient- related risk factors. That is one reason why we focus on the patients with a history of renal insufficiency. Renal insufficiency was usually defined as a decrease in eGFR and since the eGFR has to be reduced by 50% before a rise in serum creatinine occurs, an elevated serum creatinine level was used as the cut-off point for the definition for renal insufficiency[21]. In a retrospective review of 938 patients with stable renal insufficiency, the overall incidence of CIN was 6.1%, and the incidence was 4.4%, 10.5%, 10.0% for patients whose eGFR was 45-60, 30-45, and ≤30ml/min, respectively[30]. Hence special care should be taken in patients with renal insufficiency.

In order to prevent CIN, sodium bicarbonate has been proposed by various mechanisms[31,32]. Namely, how does it work remains unknown. Some potential mechanisms are that alkalinizing the tubular urine with sodium bicarbonate may attenuate free radical formation and peroxide injury[28].Oxygen free radicals and peroxide usually generate in acidic conditions, infusion of sodium bicarbonate could increase the PH of local renal tissue to neutral or slightly alkaline, thereby reducing the production of free radicals and peroxide. Merten et al[19] first introduced the administration of sodium bicarbonate in a concentration of 154mmol/L to prevent CIN. In this study, hydration regimens of 13 trials [9-17,19-21,33] were performed similarly to "Merten protocol". Although most previous systematic reviews and relevant meta-analyses demonstrated that sodium bicarbonate infusion could decrease the incidence of CIN[25,26,34-42], secondary clinical endpoints as diverse as renal replacement therapy and mortality were not ameliorated. Furthermore, a

BMJ Open: first published as 10.1136/bmjopen-2014-006989 on 17 March 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES)

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

retrospective cohort study of 7,977 patients at Mayo Clinic got a surprising result: sodium bicarbonate was associated with an increased incidence of CIN[43]. By contrast with a majority of RCTs using creatinine elevations within 48-72h after contrast exposure to define CIN, From et al extended the definition time of CIN to a week based on the fact that creatinine may peak 3 to 7d after contrast. However, this issue remains to be discussed. Because in our study, all the patients with a history of renal insufficiency, the peak of serum creatinine may advance.

In this meta-analysis, underlying sources of moderate heterogeneity should be taken into account, because the study subjects, study settings and type of contrast media were varied. In this case, subgroup analyses were conducted and the results revealed significant differences between emergency and elective procedures, the protective role of sodium bicarbonate played better in the former than latter. In a meta-analysis[42] of the effect of sodium bicarbonate for the prevention of CIN, subgroup analyses also showed a more pronounced efficacy of sodium bicarbonate in 3 trials[18,33,44] included patients undergoing emergency procedures compared with those undergoing elective procedures. But the exact mechanism by which sodium bicarbonate results in a decrease incidence of CIN is still a mystery. Maybe it's related to manner of administration and dosage. Similarly, sodium bicarbonate was more beneficial in patients who received low-osmolar contrast agents[45,46]. However, because of the significantly smaller case number of included patients who received iso-osmolar contrast media (n=1,189) compared with those received low-osmolar ones(n=2,823), the major reason responsible for the more salient effect of sodium bicarbonate is difficult to elucidate.

Although the utilization of N-acetylcysteine(NAC) has been known to reduce the incidence of CIN and the value of it has been the focus of many studies, the definitive effect of NAC is not yet established. Not a few trials and meta-analyses indicated the combination of sodium bicarbonate and NAC is superior to either regimen in

preventing of CIN. Also, three studies[20,44,47] included patients who received NAC in both groups after the infusion of sodium bicarbonate or saline and the results were in favor of sodium bicarbonate. The BINARIO[48]study indicated that hydration with sodium bicarbonate in addition to high-dose NAC in the setting of urgent PCI for STEMI was associated with a net clinical benefit. However, Yang et al[27]and Thayssen et al [49]concluded that use of NAC caused no significant reduction in the incidence of CIN. In our study, because of only one trial[20]using NAC included in the sub-analyses, the effect of which may be overestimated (OR 0.17;95%CI 0.04-0.79, P=0.024). Accordingly, more large-scale and well-designed randomized clinical trials are warranted to determine whether sodium bicarbonate plus NAC is more useful in preventing CIN than either alone.

Many studies have now shown that patients with CIN have a greater risk for the renal replacement therapy and death. In fact, almost all the dialysis and death events occurred in patients with CIN who have high-risk factors. So we could not rely on sodium bicarbonate alone to improve the bad situations caused by CIN together with basic diseases, such as renal insufficiency, diabetes mellitus. Maybe that is one vital reason why we did not find a significant difference in both requirement of dialysis and mortality. However, the lack of power of included RCTs could also be attributed to. In this meta-analysis, not all studies described renal replacement therapy and mortality and sample sizes were relatively small. So this issue needs further research.

Conclusions

Our meta-analysis demonstrates the administration of sodium bicarbonate is superior to the administration of saline in the prevention of CIN in patients with preexisting renal insufficiency undergoing procedures requiring contrast media. However, the use of sodium bicarbonate did not result in clear benefit in regard to reductions in requirement of dialysis and mortality. Therefore, more large sample trials are required to detect the efficacy of sodium bicarbonate in preventing CIN and Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

improving the clinical prognosis of patients with CIN.

Footnotes

Contributors: B.Z, L.L and WB.C searched the studies. B.Z wrote the manuscript.

L.L ,WB.C, CH.L and SX.Z reviewed, analyzed and helped writing the manuscript.

All authors contributed to the conception and design of this study.

Funding: This study was supported by grants from National Scientific Foundation of

China(No:81171329) and Guangdong Science Foundation(No: S2011010000790).

Competing interests: None.

Provenance and peer review: Not commissioned; externally peer reviewed.

Data sharing statement: No additional data are available.

References

1 Golshahi J, Nasri H, Gharipour M, et al. Contrast-induced nephropathy; A literature review[J]. J Nephropathol 2014; 3(2):51-6

2Humbert A, Kissling S, Teta D. Contrast-induced nephropathy[J].Rev Med Suisse 2013;9(389):1222-1228.

3 Mohammed NMA, Mahfouz A, Achkar K, et al. Contrast-induced nephropathy[J]. Heart views 2013; 14(3): 106-16.

4 Silva RG, Silva NG, Lucchesi F, et al. Prevention of contrast-induced nephropathy by use of bicarbonate solution: preliminary results and literature review[J].Jornal Brasileiro de Nefrologia 2010;32(3): 292-302.

5 Weisbord SD, Chen H, Stone RA, et al. Associations of increases in serum creatinine with mortality and length of hospital stay after coronary angiography[J]. JASN 2006; 17(10): 2871-2877.

6 Subedi B, Siddique MA, Zaman SM, et al. Contrast induced nephropathy in patients with pre-existing renal impairment undergoing coronary angiogram and percutaneous transluminal coronary angioplasty[J]. Mymensingh medical journal 2011;20(2): 270-274.

7 Adolph E, Holdt-Lehmann B, Chatterjee T, et al. Renal Insufficiency Following Radiocontrast Exposure Trial (REINFORCE): a randomized comparison of sodium bicarbonate versus sodium chloride hydration for the prevention of contrast-induced nephropathy[J]. Coron Artery Dis 2008;19(6): 413-419.

8 Brar SS, Shen AY, Jorgensen M, et al. Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial[J]. Jama 2008;300(9): 1038-1046. 9 Maioli M, Toso A, Leoncini M, et al. Sodium bicarbonate versus saline for the prevention of contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention[J]. J Am Coll Cardio 2008; 52(8):

599-604.

10 Vasheghani-Farahani A, Sadigh G, Kassaian SE, et al. Sodium bicarbonate plus isotonic saline versus saline for prevention of contrast-induced nephropathy in patients undergoing coronary angiography: a randomized controlled trial[J]. Am J Kidney Dis 2009;54(4): 610-618.

11 Vasheghani-Farahani A, Sadigh G, Ebrahim Kassaian S, et al. Sodium bicarbonate in preventing contrast nephropathy in patients at risk for volume overload: a randomized controlled trial[J]. J Nephrol 2010; 23(2): 216.

BMJ Open: first published as 10.1136/bmjopen-2014-006989 on 17 March 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES)

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

12 Castini D, Lucreziotti S, Bosotti L, et al. Prevention of Contrast-induced Nephropathy: A Single Center Randomized Study[J]. Clin Cardiol 2010;33(3): E63-E68. 13 Lee S W, Kim W J, Kim Y H, et al. Preventive strategies of renal insufficiency in patients with diabetes undergoing intervention or arteriography (the PREVENT Trial)[J]. Am J Cardiol 2011; 107(10): 1447-1452.

14 Hafiz AM, Jan MF, Mori N, et al. Prevention of contrast-induced acute kidney injury in patients with stable chronic renal disease undergoing elective percutaneous coronary and peripheral interventions: Randomized comparison of two preventive strategies[J]. Catheter Cardiovasc Interv 2012;79(6): 929-937.

BMJ Open: first published as 10.1136/bmjopen-2014-006989 on 17 March 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES)

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

15 Gomes VO, Lasevitch R, Lima VC, et al. Hydration with sodium bicarbonate does not prevent contrast nephropathy: a multicenter clinical trial[J]. Arg Bras Cardiol 2012;99(6): 1129-1134.

16 Boucek P, Havrdova T, Oliyarnyk O, et al. Prevention of contrast-induced nephropathy in diabetic patients with impaired renal function: A randomized, double blind trial of sodium bicarbonate versus sodium chloride-based hydration[J]. Diabetes Res Clin Pract 2013; 101(3): 303-308.

17 Kristeller JL, Zavorsky GS, Prior JE, et al. Lack of effectiveness of sodium bicarbonate in preventing kidney injury in patients undergoing cardiac surgery: a randomized controlled trial[J]. Pharmacotherapy 2013; 33(7): 710-717. 18 Ueda H, Yamada T, Masuda M, et al. Prevention of contrast-induced nephropathy by bolus injection of sodium bicarbonate in patients with chronic kidney disease undergoing emergent coronary procedures[J]. Am J Cardiol 2011;107(8): 1163-1167. 19 Merten GJ, Burgess WP, Rittase RA, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: an evidence-based protocol[J]. Crit Pathw Cardiol 2004;3(3): 138-143.

20 Briguori C, Airoldi F, D'Andrea D, et al. Renal Insufficiency following contrast media administration trial (REMEDIAL) A randomized comparison of 3 preventive strategies [J]. Circulation 2007; 115(10): 1211-1217.

21 Klima T, Christ A, Marana I, et al. Sodium chloride vs. sodium bicarbonate for the prevention of contrast medium-induced nephropathy: a randomized controlled trial[J]. Eur Heart J 2012;33(16): 2071-2079.

22 Kooiman J, Sijpkens YW, de Vries JP, et al. A randomized comparison of 1-h sodium bicarbonate hydration versus standard peri-procedural saline hydration in patients with chronic kidney disease undergoing intravenous contrast-enhanced computerized tomography[J]. Nephrol Dial Transplant 2014; 29(5):1029-36.

1 2	
3 4	23 Tarr
5 6	sodium
7 8	renal ir
9 10	2009;1
11 12	24 Mot
13 14	bicarbo
15 16	underg
17 18	25 Mei
19 20	contras
21 22	26 Triv
23 24	preven
25 26	contro
27 28	27 Yan
29 30	nephro
31 32	(9):180
33 34	28 Atki
35 36	Nephro
37 38	29 Anc
39 40	Media
41 42	741018
43 44	30 Mu
45 46	patient
47 48	2012; 2
49 50	31 Mc
51 52	nephro
53 54	32 Bur
55 56	for Sali
57 58	
59 60	
	_

nura A, Goto Y, Miyamoto K, et al. Efficacy of single-bolus administration of n bicarbonate to prevent contrast-induced nephropathy in patients with mild nsufficiency undergoing an elective coronary procedure[J]. Am J Cardiol .04(7): 921-925.

tohiro M, Kamihata H, Tsujimoto S, et al. A new protocol using sodium onate for the prevention of contrast-induced nephropathy in patients oing coronary angiography[J]. Am J Cardiol 2011; 107(11): 1604-1608. er P, Ko DT, Tamura A, et al. Sodium bicarbonate-based hydration prevents st-induced nephropathy: a meta-analysis[J]. BMC Med 2009; 7(1): 23. redi H, Nadella R, Szabo A. Hydration with sodium bicarbonate for the tion of contrast-induced nephropathy: a meta-analysis of randomized lled trials[J].Clin Nephrol 2010;74(4):288-296.

g K,Liu W, Ren W, et al. Different interventions in preventing contrast-induced opathy after percutaneous coronary intervention[J]. Int Urol Nephrol 2014;46)1-7.

ins JL. Effect of sodium bicarbonate preloading on ischemic renal failure. on 1986;44(1):70-74.

lreucci, Michele, Richard Solomon, et al. Side Effects of Radiographic Contrast Pathogenesis, Risk Factors, and Prevention[J].Biomed Res Int 2014;2014:

8

rakami R, Hayashi H, Sugizaki K, et al. Contrast-induced nephropathy in s with renal insufficiency undergoing contrast-enhanced MDCT[J]. Eur Radiol 22(10): 2147-2152.

Cullough PA, Adam A, Becker CR, et al. Risk prediction of contrast-induced opathy[J]. Am J Cardiol 2006;98(6): 27-36.

gess WP, Walker PJ. Mechanisms of Contrast-Induced Nephropathy Reduction ine (NaCl) and Sodium Bicarbonate (NaHCO3)[J]. Biomed Res Int 2014;2014:

BMJ Open: first published as 10.1136/bmjopen-2014-006989 on 17 March 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES)

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

33 Masuda M, Yamada T, Mine T, et al. Comparison of usefulness of sodium bicarbonate versus sodium chloride to prevent contrast-induced nephropathy in patients undergoing an emergent coronary procedure[J]. Am J Cardiol 2007;100(5): 781-786.

34 Hogan SE, L'Allier P, Chetcuti S, et al. Current role of sodium bicarbonate–based preprocedural hydration for the prevention of contrast-induced acute kidney injury: A meta-analysis[J]. Am Heart J 2008;156(3): 414-421.

35 Joannidis M,Schmid M, Wiedermann CJ. Prevention of contrast media-induced nephropathy by isotonic sodium bicarbonate: a meta-analysis[J].Wien Klin Wochenschr 2008;120(23-24):742-8

36 Ho KM, Morgan DJ. Use of isotonic sodium bicarbonate to prevent radiocontrast nephropathy in patients with mild pre-existing renal impairment: a meta-analysis [J].Anaesth Intensive Care 2008;36(5): 646-653.

37 Navaneethan SD, Singh S, Appasamy S, et al. Sodium bicarbonate therapy for prevention of contrast-induced nephropathy: a systematic review and meta-analysis [J]. Am J Kidney Dis 2009;53(4): 617-627.

38 Brar SS, Hiremath S, Dangas G, et al. Sodium bicarbonate for the prevention of contrast induced-acute kidney injury: a systematic review and meta-analysis[J]. Clinical Journal of the American Society of Nephrology 2009; 4(10): 1584-1592.

39 Kanbay M, Covic A, Coca SG, et al. Sodium bicarbonate for the prevention of contrast-induced nephropathy: a meta-analysis of 17 randomized trials[J]. Int Urol Nephrol 2009;41(3): 617-627.

40 Hoste EA, De Waele JJ, Gevaert SA, et al. Sodium bicarbonate for prevention of contrast-induced acute kidney injury: a systematic review and meta-analysis[J]. Nephrology Dialysis Transplantation 2010;25(3): 747-758.

41 Kunadian V, Zaman A, Spyridopoulos I, et al. Sodium bicarbonate for the

prevention of contrast induced nephropathy: a meta-analysis of published clinical trials[J]. Eur J Radiol 2011;79(1): 48-55.

42 Jang JS, Jin HY, Seo JS, et al. Sodium bicarbonate therapy for the prevention of contrast-induced acute kidney injury–a systematic review and meta-analysis[J]. Circ J 2011; 76(9): 2255-2265.

43 From AM, Bartholmai BJ, Williams AW, et al. Sodium bicarbonate is associated with an increased incidence of contrast nephropathy: a retrospective cohort study of 7977 patients at Mayo Clinic[J]. Clinical Journal of the American Society of Nephrology 2008;3(1): 10-18.

44 Recio-Mayoral A, Chaparro M, Prado B, et al. The reno-protective effect of hydration with sodium bicarbonate plus N-acetylcysteine in patients undergoing emergency percutaneous coronary intervention: the RENO Study[J]. J Am Coll Cardiol 2007;49(12): 1283-1288.

45 Jo SH, Youn TJ, Koo BK, et al. Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial[J]. J Am Coll Cardiol 2006; 48(5): 924-930.

BMJ Open: first published as 10.1136/bmjopen-2014-006989 on 17 March 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES)

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

46 McCullough PA, Bertrand ME, Brinker JA, et al. A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media[J]. J Am Coll Cardiol 2006;48(4): 692-699.

47 Mahmoodi K, Sohrabi B, Ilkhchooyi F, et al. The efficacy of hydration with normal saline versus hydration with sodium bicarbonate in the prevention of contrast-induced nephropathy[J]. Heart views 2014; 15(2): 33.

48 Leone AM, De Caterina AR, Sciahbasi A, et al. Sodium bicarbonate plus N-acetylcysteine to prevent contrast-induced nephropathy in primary and rescue percutaneous coronary interventions: the BINARIO (Blcarbonato e N-Acetil-cisteina nell'infaRto mlocardico acutO) study[J].EuroIntervention, 2012; 8(7): 839-847.

, len; Latyloysteine Latial Infarction A Pros, Latve 2014;7(2): 216-224 49 Thayssen P, Lassen JF, Jensen SE, et al. Prevention of Contrast-Induced

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

Chudu Casas		Age(years)		DM	HT	Baseline S	cr(mg/dl)	eGFR(ml/min/1.73m²)		
Study	Cases	Bicarbonate	Saline	⁻ Male(%) % %	Bicarbonate	Saline	Bicarbonate	Saline		
Merten	119	66.7*	69.2*	73/76	50/46	NA	1.89*	1.71*	41.0*	45.0*
Ozcan	176	68.0*	70.0*	76/75	42/48	75/81	1.36*	1.40*	NA	NA
Masuda	59	75.0±8.0	76.0±11.0	63/59	27/35	NA	1.31±0.52	1.32±0.65	40.2±15.4	38.7±15
REMEDIAL	219	70.0±9.0	71.0±9.0	88/81	49/55	92/87	2.04*	1.95*	32.0±7.0	71.0±9.
Adolph	145	70.1±8.4	72.7±6.6	75/81	37/28	83/91	1.54±0.51	1.57±0.36	NA	NA
Brar	323	71.0*	71.0*	62/65	43/46	NA	1.49#	1.49#	47.7#	48.3#
Maioli	502	74.0*	74.0*	57⁄61	25/23	59/57	1.21±0.30	1.20±0.30	NA	NA
Tamura	144	72.3±9.9	73.3±7.7	92/83	60/57	85/83	1.36±0.18	1.38±0.19	40.0±7.5	38.2±0
Vasheghani	265	62.9±10.0	63.8±9.0	84/82	22/21	30/41	1.63±0.32	1.66±0.50	46.4±12.0	45.4±12
Castini	103	70.0±8.3	72.7±8.2	85/84	35/20	71/78	1.59±0.38	1.49±0.30	46.9±12.8	49.9±10
Vasheghani(2)	72	61.4#	62.7#	78/81	33/38	66/71	1.77#	1.71#	42.7#	44.2#
Motohiro	155	71.0±9.0	74.0±7.0	76/64	56/63	86/83	1.54±0.43	1.55±0.44	45.7±12.9	42.8±13
PREVENT	382	65.8*	67.5*	71/71	100/100	77⁄80	1.50*	1.50*	46.0*	46.0*
Ueda	59	77.0±9.0	75.0±10.0	77/79	10/10	NA	1.32±0.46	1.51±0.59	42.4±11.5	38.7±12
Klima	176	78.0*	75.0*	66/62	39/34	90/81	1.60*	1.60*	43.1#	43.0#
Gomes	301	64.1±12.0	64.5±12.0	15/75	29/30	77/74	1.50±0.40	1.49±0.50	50.5±13.0	51.9±1
Hafiz	320	74.0*	73.0*	57/57	49/45	95/94	1.65*	1.60*	41.5*	40.5*
Kristeller	92	72.0±11.0	73.0±11.0	64/52	52/38	89/92	NA	NA	48.9#	49.4#
Boucek	120	63.0#	67.0#	75/75	NA	NA	1.92#	1.81#	43.6#	44.6#
Kooiman	548	71.6#	72.5#	60/61	27/27	NA	NA	NA	49.9#	50.9#

Note: DM=diabetes mellitus HT=hypertension eGFR=estimated glomerular filtration rate NA= not applicable

*median value #mean value

BMJ Open: first published as 10.1136/bmjopen-2014-006989 on 17 March 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

lective diagnostic interventional rocedures lective CAG/PCI mergency	SB vs SC SB vs SC	BicarbonateSalineNANAIopamidol,nonionic,Low-osmolar100*100*Ioxaglate,ionic,Low-osmolar	$1 \text{ ml} \cdot \text{kg}^{-1} \cdot \text{h}^{-1}$ for 6h before and after	Definition of CIN ¹ Scr个≥25% within 2 Scr个>0.5mg/dl or
nterventional rocedures lective CAG/PCI mergency		Iopamidol,nonionic,Low-osmolar 100* 100*	for 6h after the procedure of SB or SC 1ml·kg ⁻¹ ·h ⁻¹ for 6h before and after	Scr个≥25% within 2
mergency	SB vs SC		-	Scr个>0.5mg/dl or
			the procedure of SB or SC	25% within 2d
	SB vs SC	112±89 120±61 Iopamidol,nonionic,Low-osmolar	3ml·kg ⁻¹ ·h ⁻¹ for 1h before and 1ml·kg ⁻¹ ·h ⁻¹ for 6h after the procedure of SB or SC	Scr个>0.5mg/dl or 25% within 2d
CI /peripheral	SB+NAC vs NS+NAC	169±92 179±9 lodixanol,nonionic,lso- osmolar	3ml·kg ⁻¹ ·h ⁻¹ for 1h before and 1ml·kg ⁻¹ ·h ⁻¹ for 6h after:SB; 1ml·kg ⁻¹ ·h ⁻¹ for 12h before and 12h after:NS	Scr个≥25% within 2
lective CAG/PCI	SB vs SC	141±50 138±52 Iodixanol,nonionic,lso- osmolar	2ml·kg ⁻¹ ·h ⁻¹ for 2h before and 1ml·kg ⁻¹ ·h ⁻¹ for 6h after the procedure of SB or SC	Scr个>0.5mg/dl or 25% within 2d
lective CAG	SB vs SC	126* 137* Ioxilan,nonionic,Iso- osmolar	3ml·kg ⁻¹ ·h ⁻¹ for 1h before and 1.5ml·kg ⁻¹ ·h ⁻¹ for 4h after the procedure of SB or SC	eGFR↓>25% within 4d
lective CAG/PCI	SB vs IS	160* 170* Iodixanol,nonionic,Iso- osmolar	$3ml\cdot kg^{-1}\cdot h^{-1}$ for 1h before and $1ml\cdot kg^{-1}\cdot h^{-1}$ for 6h after:SB; $1ml\cdot kg^{-1}\cdot h^{-1}$ for 12h after:IS	Scr个≥0.5mg/dl within 5d
Bo lective CAG/PCI	olus SB+SC vs SC	82±40 88±45 Iohexol,nonionic,Low-osmolar	Single-bolus SB 20ml for 5min before and SC 1ml·kg ⁻¹ ·h ⁻¹ for 12h pre- and post- procedure; 1ml·kg ⁻¹ ·h ⁻¹ for 12h pre- and post-procedure of SC	Scr个>0.5mg/dl or 25% within 3d
lective CAG S	SB+Is vs IS	115±41 113.2±36 Iohexl,nonionic,Low-osmolar	3ml·kg ⁻¹ ·h ⁻¹ for 1h before and 1ml·kg ⁻¹ ·h ⁻¹ for 6h after in both groups	Scr个≥0.5mg/dl or 25% within 2d
lective CAG/PCI	SB vs SC	179±125 196±128 Iodixanol,nonionic,Low-osmolar	3ml·kg ⁻¹ ·h ⁻¹ for 1h before and 1ml·kg ⁻¹ ·h ⁻¹ for 6h after:SB; 1ml·kg ⁻¹ ·h ⁻¹ for 12h before and after:SC	Scr个≥25% within 5

Tab 1 Continued

Procedure	Interventions –	Contrast type and Volume(ml)		 Hydration regimen 	Definition of CIN	
Procedure	interventions –	Bicarbonate	Saline	- Hydration regimen	Demittion of City	
Elective CAG	SB+half SC vs half SC	112# Iohexol,n Low-os		3ml·kg ⁻¹ ·h ⁻¹ for 1h before and 1ml·kg ⁻¹ ·h ⁻¹ for 6h after the procedure of 75ml SB to1L of 0.45%SC; 1075ml 0.45%SC	Scr个≥0.5mg/dl or 25% within 2d	
Elective CAG/PCI	SB+SC vs SC	140±50 Iopamidol, Low-os		1ml·kg ⁻¹ ·h ⁻¹ SC 12h before and 1ml·kg ⁻¹ ·h ⁻¹ SB from 3h pre-to 6h post-procedure, then 1ml·kg ⁻¹ ·h ⁻¹ SC for 12h; 1ml·kg ⁻¹ ·h ⁻¹ SC 12h pre- and 12h post- procedure	Scr↑≥0.5mg/dl or>25% within 2d	
Elective CAG/ angioplasty/ endovascular intervention	SB vs SC	113* Iodixanol, Low-os		3ml·kg ⁻¹ ·h ⁻¹ for 1h before and 1ml·kg ⁻¹ ·h ⁻¹ for 6h after:SB; 1ml·kg ⁻¹ ·h ⁻¹ for 12h:SC	Scr↑≥0.5mg/dl or>25% within 2d	
Emergency CAG/ PCI	SB vs SC	116±63 Iopamido Low-os		Bolus 0.5mg/ml SB before and SC 1ml·kg ⁻¹ ·h ⁻¹ for 6h during and after in both groups	Scr个≥0.5mg/dl or >25% within 2d	
Elective CAG/ PCI/ PTA/CT/ PAG	SB vs SC	100* Iopromide/i Iso/Low-		3ml·kg ⁻¹ ·h ⁻¹ for 1h before and 1ml·kg ⁻¹ ·h ⁻¹ for 6h after:SB; 1ml·kg ⁻¹ ·h ⁻¹ for 24h:SC	Scr个≥0.5mg/dl or 25% within 2d	
Elective CAG/PCI	SB vs NS	124±65 Hexabrix/I Low-os	-	3ml·kg ⁻¹ ·h ⁻¹ for 1h before and 1ml·kg ⁻¹ ·h ⁻¹ for 6h after the procedure of SB or NS	Scr个≥0.5mg/dl within 2d	
Elective CAG/ PAG/ intervention	SB±NAC vs NS±NAC	110* Iodixanol/lopar nonionic,Lo		3ml·kg ⁻¹ ·h ⁻¹ for 1h before and 1ml·kg ⁻¹ ·h ⁻¹ for 6h after:SB; 1ml·kg ⁻¹ ·h ⁻¹ for 12h before and 12h after:NS	Scr个>0.5mg/dl o 25% within 2d	
Elective CPB	SB vs IS	74# N.	83# A	3ml·kg ⁻¹ ·h ⁻¹ for 1h before and 1ml·kg ⁻¹ ·h ⁻¹ for 6h after the procedure of SB or IS	Scr $\uparrow \ge 0.3$ mg/dl or 50% or Urine outp < 0.5 ml·kg ⁻¹ ·h ⁻¹ (>60 within 5d	
Elective CAG/ Lower-limb angiography and /or angioplasty	SB vs NS	115# Iodinated, Iow-os		3ml·kg ⁻¹ ·h ⁻¹ for 1h before and 1ml·kg ⁻¹ ·h ⁻¹ for 6h after the procedure of SB or SC	Scr个≥0.5mg/dl or 25% within 2d	
Elective CECT	SB vs IS	105.7# Iomeprol/I Iodixanol,Lo		250ml SB for 1h before; 1000ml IS before and 1000ml IS after	Scr↑>0.5mg/dl c 25% within 4d	

BMJ Open: first published as 10.1136/bmjopen-2014-006989 on 17 March 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

2	
3	
4	
3 4 5 6 7 8 9	
5	
6	
7	
8	
0	
9	
10	
11	
40	
12	
13	
14	
15	
10	
16	
17	
18	
9 9 10 11 12 13 14 15 16 17 18 20 21 22 23 24 25 26 27 28 20 31 32	
19	
20	
21	
20	
22	
23	
24	
25	
20	
26	
27	
28	
20	
29	
30	
31	
00	
32	
33	
34	
07	
35	
36	
37	
20	
30	
39	
30 31 32 33 34 35 36 37 38 39 40	
41	
42	
43	
44	
44	
46	
47	
-	
49	
50	
-	
52	
53	
54	
55	
56	
57	
58	
50	
59	
60	

Tab 2 Quality assessment of included studies

Included trials	Trial described as randomized (1=yes, 0=no)	Randomized method described & appropriate (1=yes, 0=no)	Allocation concealment described† (1=yes, 0=no)	Allocation concealment described & appropriate (1=yes, 0=no)	Trial described as double blind (1=yes, 0=no)	Double blind method described & appropriate (1=yes,0=no)	Withdrawals & Dropouts described (1=yes,0=no)	Jadad score * 4 2 4 5 5 5 4 4 4 4 3
Merten	1	1	0	0	0	0	1	4
Ozcan	1	0	0	0	0	0	1	2
Masuda	1	1	0	0	0	0	1	4
REMEDIAL	1	1	0	0	1	0	1	5
Adolph	1	1	0	0	1	0	1	5
Brar	1	1	1	1	0	0	1	5
Maioli	1	1	1	1	0	0	0	4
Tamura	1	1	0	0	0	0	1	4
/asheghani	1	1	0	0	1	0	0	4
Castini	1	1	0	0	0	0	0	3
asheghani(2)	1	1	0	0	1	0	0	4
Motohiro	1	1	0	0	0	0	1	4
PREVENT	1	1	0	0	0	0	1	4
Ueda	1	1	0	0	0	0	0	3
Klima	1	0	1	1	0	0	0	3
Gomes	1	0	1	1	0	0	0	3
Hafiz	1	1	0	0	0	0	1	4
Kristeller	1	1	1	1	1	0	0	5
Boucek	1	1	1	1	1	0	1	6
Kooiman	1	1	0	0	0	0	1	4
		ed from Jadad Sco sessment of inclu			e trial is describ	ed &appropriate	2	

Tab 3 Subgroup analyses: to assess the effect of sodium bicarbonate in various conditio	ns
---	----


Subgroups	Trials/patients	OR(95%CI)	Test for overall effect	Heterogeneity
Type of contrast				
Low-osmolar	14/2823	0.59[0.37,0.93]	Z=2.26(P=0.024)	X ² =26.61,df=13(P=0.014),l ² =51%
Iso-osmolar	4/1189	0.76[0.43,1.34]	Z=0.93(P=0.351)	X ² =4.67, df=3(P=0.198),I ² =36%
Setting				
Elective	18/4162	0.76[0.54,1.06]	Z=1.62(P=0.105)	X ² =29.54,df=17(P=0.030),l ² =43%
Emergency	2/118	0.16[0.05,0.51]	Z=3.11(P=0.002)	X ² =0.07,df=1(P=0.784),l ² =0%
Using NAC or not				
Use	1/219	0.17[0.04,0.79]	Z=2.26(P=0.024)	Not applicable
Non-use	18/3741	0.71[0.48,1.03]	Z=1.80(P=0.071)	X ² =33.13,df=17(P=0.011),l ² =49%
Publication year				
Before 2008	4/573	0.19[0.09,0.41]	Z=4.26(P=0.000)	X ² =1.06,df=10(P=0.788),I ² =0%
After 2008	16/3707	0.85[0.62,1.16]	Z=1.03(P=0.302)	X ² =22.13,df=15(P=0.105),l ² =32%
Manner of adminis	stration			
Continuous	18/4077	0.75[0.53,1.05]	Z=1.69(P=0.091)	X ² =30.21,df=17(P=0.025),l ² =44%
Bolus	2/203	0.15[0.04,0.54]	Z=2.90(P=0.004)	X ² =0.23,df=1(P=0.632),I ² =0%

15[0.04,0.54] Z=Z.90(r=0.00..,

BMJ Open: first published as 10.1136/bmjopen-2014-006989 on 17 March 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) .

data mining, AI training, and similar technologies

Protected by copyright, including for uses related to text and









Fig 1 Selecting flow chart showing the number of excluded trials and the reasons, as well as the number of included trials









BMJ Open: first published as 10.1136/bmjopen-2014-006989 on 17 March 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES). Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

Page 26 of 56

BMJ Open: first published as 10.1136/bmjopen-2014-006989 on 17 March 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES)

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies









Fig 4 The influence of an individual study on the overall estimates

Page 27 of 56





PRISMA 2009 Checklist

5 Section/topic	#	Checklist item	Reported on page #
7 TITLE			
8 9 Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
11 Structured summary 12 13	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2-3
¹⁶ Rationale	3	Describe the rationale for the review in the context of what is already known.	4
1 <mark>8</mark> Objectives 19	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	4
20 METHODS			
²¹ Protocol and registration 22 28	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	NA
24 Eligibility criteria 25	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5
26 Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5
2 ⁸ 29 30	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	4-5
31 Study selection 32	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	5
³³ Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	5-6
35 36 Data items 37	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	6
38 Risk of bias in individual 39 studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	6
40 Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	6
42 Synthesis of results 43	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	6
44 45			
46	.səibo	londər າ <u>ຮ່ມເຕັ້ນເອກເດັດເປັນເຈັດໃນເປັນເປັນເປັນເປັນເປັນເປັນເປັນເປັນເປັນເປັ</u>	1
40 48 I əb əupidqsıgoildi8 əɔnəg 42		first published as 10.51136/md.neqoimd/\:qtth mont bebsolnwold.5102. Downloaded from http://dth.op.on.jon.2014. (SEBA)	:nəqO LMB

Page 29 of 56



4

PRISMA 2009 Checklist

4 5 6	#	Checklist item	Reported on page #		
7 Risk of bias across studies 8	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	6		
9 Additional analyses 10	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	6		
13 Study selection 14	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	Figure1		
15 Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	Table1		
18 Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	Fig2/3a/3b		
19 Results of individual studies 20 21	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	7- 8Figure2/3a /3b		
22 23 Synthesis of results 24 25	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	7- 8Figure2/3a /3b		
$\frac{26}{27}$ Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	7		
28 Additional analysis 29	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	8Figure 4 /Table3		
3 32 Summary of evidence 33	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	8-11		
34 Limitations 35	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	11		
³⁶ Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	11		
38 FUNDING	-				
39 40 41	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	12		
⁺ ∠ doi 10 1371/iournal pmed1000097	f J, Altm	an DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med	6(6): e1000097.		
43 44		For more information, visit: www.prisma-statement.org.			
4 5 9 Page 2 of 2					
Protected by copyrights inguidation technications in the section of the standard and the static and static and section of the static and static and section of the static and					
10 18 I ab aupirqargoildi8 anago 136, 2025, 202, 2015, Downloaded from http://mgogo.new.ine 13, 2025 at Agence Bibliographique de la 18 12 I ab aupirqargoildi8 anago 1.05 at 2015, 2015, 2015, 2015, 2015, 2015, 2015, 2015, 2015, 2015, 2015, 2015, 20 14 I ab aupirdargoildi8 anago 1.05 at 2015, 2015, 2015, 2015, 2015, 2015, 2015, 2015, 2015, 2015, 2015, 2015, 20					

BMJ Open

The efficacy of sodium bicarbonate preventing contrast-induced nephropathy in patients with preexisting renal insufficiency: a meta-analysis

Bin Zhang^{1,2}, Long Liang^{1,2}, Wenbo Chen², Changhong Liang², Shuixing Zhang².

1Graduate College, Southern Medical University, 510515 Guangzhou, China 2Department of Radiology, Guangdong Academy of Medical Sciences/Guangdong General Hospital, No. 106 Zhongshan Er Road, 510080 Guangzhou, Guangdong Prov, People's Republic of China

Corresponding author: Shuixing Zhang, Department of Radiology, Guangdong

Academy of Medical Sciences/Guangdong General Hospital, No. 106 Zhongshan Er

Road, 510080 Guangzhou, Guangdong Prov, People's Republic of China

E-mail: shui7515@hotmail.com

Tel: +86 20 83870125 Fax: +86 20 83870125

Key words: Sodium bicarbonate; Saline; Contrast-induced nephropathy;

Renal insufficiency; Meta-analysis

Text word count:2884

Abstract word count:297

Running head: The efficacy of sodium bicarbonate in preventing CIN

ABSTRACT

Objective: The primary objective of this meta-analysis was to explore the efficacy of sodium bicarbonate in preventing contrast-induced nephropathy (CIN) and assess if it could reduce the risks of dialysis and mortality, thus improving the clinical prognosis of patients with CIN.

Design: Meta-analysis

Participants: A comprehensive literature search of PubMed, Medline and Cochrane Library was conducted through August 2014.The effect estimate was expressed as pooled odds ratio(OR) with 95% confidence interval(CI), using the random-effects model.

Results: A total of 20 clinical trials consisting of 4,280 patients were absorbed into this study. Pre-procedural hydration with sodium bicarbonate was associated with a significant decrease in the incidence of CIN among patients with preexisting renal insufficiency (OR 0.67; 95%CI 0.47-0.96; P=0.027). However, moderate heterogeneity was noted among the included trials(I²=48%;P=0.008). Therefore, we performed subgroup analyses and indicated a more pronounced effect of sodium bicarbonate in studies using low-osmolar contrast agents (OR 0.59; 95%CI: 0.47-0.93,P=0.024) compared with those using iso-osmolar ones(OR 0.76; 95%CI: 0.43-1.34,P=0.351). Similarly, a lower odds of CIN with sodium bicarbonate occurred in studies including exclusively patients undergoing emergency procedures (OR 0.16; 95%CI: 0.05-0.51, P=0.002) compared with those undergoing elective ones (OR 0.76;95%CI:0.54-1.06, P=0.105). Furthermore, sodium bicarbonate played a more active role in patients

BMJ Open: first published as 10.1136/bmjopen-2014-006989 on 17 March 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) .

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

given bolus injection before procedures (OR 0.15; 95%CI: 0.04-0.54, P=0.004) compared with continuous infusion(OR 0.75; 95%CI:0.53-1.05,P=0.091).

Sodium bicarbonate plus N-acetylcysteine (NAC) (OR 0.17; 95%CI:0.04-0.79,P=0.024) outweighed sodium bicarbonate alone (OR 0.71;95%CI:0.48-1.03,P=0.071).The effect of sodium bicarbonate was considered greater in papers published before 2008(OR

BMJ Open: first published as 10.1136/bmjopen-2014-006989 on 17 March 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) .

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

0.19;95%CI:0.09-0.41,P<0.0001) than after 2008(OR 0.85; 95%CI: 0.62-1.16, P=0.302). However, no significant difference was found in the mortality (OR 0.69;95%CI:0.36-

1.32,P=0.263)and need for dialysis(OR 1.08;95%CI:0.52-2.25,P=0.841).

Conclusions: Sodium bicarbonate is effective in preventing CIN among patients with preexisting renal insufficiency. However, it failures to lower the risks of dialysis and mortality and thus cannot improve the clinical prognosis of patients with CIN.

Article summary

Article focus:

• To explore the efficacy of sodium bicarbonate in preventing contrast-induced nephropathy.

• To assess if sodium bicarbonate could reduce the risks of dialysis and mortality, thus improving the clinical prognosis of patients with CIN.

Key messages:

• Sodium bicarbonate is effective in preventing CIN among patients with preexisting renal insufficiency.

• Infusion of sodium bicarbonate failures to lower the risks of dialysis and mortality.

Strengths and limitations of this study

• In this updated meta-analysis, we demonstrate that pre-procedural hydration with sodium bicarbonate is associated with a significant decrease in the incidence of CIN among patients with preexisting renal insufficiency.

- In this study, we find that sodium bicarbonate failures to lower the risks of dialysis and mortality and thus cannot improve the clinical prognosis of patients with CIN.
- New Jadad Scale after revision was used to assess the quality of articles.
- No publication bias.
- However, moderate heterogeneity was noted among the included trials.

Keywords: Sodium bicarbonate; Saline; Contrast-induced nephropathy;

Renal insufficiency; Meta-analysis

Introduction

Contrast-induced nephropathy is the third leading cause of in-hospital acute kidney injury[1-3], which is a serious complication of angiographic procedures resulting from the administration of contrast media. Although the definition of CIN is various, CIN is usually defined as an increase in serum creatinine level of 25% or an increase of 0.5mg/dl (or 44μ mol/L) from baseline within 48-72h of contrast exposure. It results in increased morbidity, prolonged hospital stay, and increased healthcare expenditure and is associated with a higher mortality[4].

The incidence of CIN in the general population is low, but increases exponentially in patients with high-risk factors, such as preexisting renal insufficiency, diabetes mellitus[5]. In a recent study, 21.7% of preexisting chronic renal insufficiency group and 6.3% of no preexisting chronic renal insufficiency group developed CIN[6]. Thus, baseline renal insufficiency was a significant predisposing factor of CIN. BMJ Open: first published as 10.1136/bmjopen-2014-006989 on 17 March 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) .

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

To prevent CIN, sodium bicarbonate-based hydration has been proposed as one of the feasible therapies. According to recent studies, some of them suggested that for prevention of CIN, sodium bicarbonate elicited more protective effect compared with sodium chloride, but others did not [7-17]. Although most previous meta analyses were on the side of sodium bicarbonate with possible publication bias, none of them focused on the patients with preexisting renal insufficiency. Therefore, we performed this meta-analysis to test the efficacy of sodium bicarbonate in preventing of contrast-induced nephropathy among patients with renal insufficiency undergoing various procedures that need contrast agents. What's more, differences in need for dialysis and post-procedural death between two arms were also compared in this study.

Methods

Data Sources and Searches

We searched PubMed, Medline, Cochrane Library from 2004 through to 1 August

2014. Medical subject headings and keyword searches included the terms "contrast induced nephropathy", "sodium bicarbonate", "sodium chloride", "saline", "acute kidney injury", "renal failure". Reference lists of selected articles were reviewed for other potentially relevant citations. In addition, top 50 citations for each identified relevant study were searched by using the "related articles" function of PubMed.

Study Selection

Firstly, two investigators(B.Z and L.L) independently reviewed the titles and abstracts of all studies searched to identify all potentially relevant ones. Secondly, the online publications obtained from preliminary selection were reviewed in full text by the same two investigators to assess if studies met the following inclusion criteria: comparison of sodium bicarbonate versus sodium chloride or saline, RCT, age≧8 years, clinical end point assessment included CIN, patients with preexisting renal insufficiency: defined as a serum creatinine concentration of >1.1 mg/dl or estimated glomerular filtration rate(eGFR)<60ml/min[18]or creatinine clearance rate<60ml/min [9]. Reviewers were not blinded to study authors or outcomes. Final inclusion of studies was based on the agreement of both reviewers.

Data Extraction and Quality Assessment

Two reviewers(B.Z and WB.C) extracted relevant information from the literatures including baseline clinical characteristics(mean age, the percentage of males, risk factors other than renal insufficiency, baseline Scr, eGFR, procedures, interventions, type and volume of contrast media , hydration regimen, definition of CIN)(Tab1) and data on primary(the incidence of CIN) and secondary outcomes, such as need for dialysis, mortality. CIN was defined variously in studies, but most of them described it as a absolute or relative increase in the level of serum creatinine. Three studies defined CIN as a rise in serum creatinine by 25% or more within 2-5d of contrast exposure [12,19,20]. Thirteen studies regarded an increase of 0.5mg/dl or 25% in Scr within 2-4d of contrast. Two studies considered a elevated Scr of 0.5mg/dl after the

procedures[9, 15]. However, two other trials presented were different from all above, a decrease in eGFR of 25% within 4d and an absolute increase in Scr of at least 0.3 mg/dl or 50% or Urine output< $0.5 \text{ml} \cdot \text{kg}^{-1} \cdot \text{h}^{-1}$ (>6h) within 5d were selected to define CIN, respectively[8,17]. We assessed the quality of articles using New Jadad Scale after revision(Tab 2).

Data Synthesis and Analysis

The data from included studies were combined and expressed as pooled OR with 95%CI. All analyses were performed on an "intention-to-treat" basis. Initially, fixed -effects model (Mantel-Haenzel method) was used in this meta-analysis. We evaluated the heterogeneity across studies with the Q and I² statistics. If P value<0.1, statistically significant heterogeneity was considered. The I² statistic was used to quantify the magnitude of heterogeneity, with values of 0-30%,31-50% and greater than 50% representing mild, moderate and substantial heterogeneity, respectively. The outcome of fixed-effects model analysis demonstrated a statistical heterogeneity, so we selected random-effects model (Dersimonian and Laird method).

Considering of the clinical and statistical heterogeneity across studies, subgroup analyses were performed to assess the effect of sodium bicarbonate in various conditions, such as low-osmolar vs.iso-osmolar contrast agent, emergency vs.elective procedures, article published before vs. after 2008, and continuous vs.bolus infusion of sodium bicarbonate (Tab 3). An influence analysis was carried out to evaluate how robust the pooled estimator is after removal of individual studies(Fig 4). An individual study is suspected of excessive influence if the point estimate of its omitted analysis lies outside the 95%CI of the summary analysis.Publication bias was assessed using Begg' funnel plot and Egger' regression asymmetry test(Fig 5). All statistical analyses were conducted using STATA software, version 12.0(Stata Corp LP,College Station, Texas).

BMJ Open: first published as 10.1136/bmjopen-2014-006989 on 17 March 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

Results

A total of 837 articles were reviewed and 20 studies met the inclusion criteria were absorbed into this study finally(Fig 1).

A detailed description of the baseline characteristics of the included studies is given in Tab 1. Patients in most studies underwent coronary angiography or Interventional procedures. There were also seven studies depicted peripheral procedures, angioplasty, cardiopulmonary bypass and CT[8,18,19,21-24]. The sodium bicarbonate hydration regimen in thirteen studies was described as same as Merten et al: the infusion of sodium bicarbonate at rate of 3ml·kg⁻¹·h⁻¹ for 1h before and 1ml·kg⁻¹·h⁻¹ for 6h after the procedure.

Primary Outcome

CIN occurred in a total of 158 patients in the 2,130 patients of the sodium bicarbonate arm compared with that of 217 patients in the 2,150 patients who received saline, a lower overall incidence of CIN was found in the sodium bicarbonate group(Fig 2). The pooled OR was 0.67 (95%CI:0.47-0.96; P=0.027) also in favor of sodium bicarbonate(Fig 2).

However, moderate heterogeneity across studies was observed (I²=48%,P=0.008) (Fig 2).

Therefore, subgroup analyses were constructed and suggested a more pronounced effect of sodium bicarbonate in studies using low-osmolar contrast media(OR 0.59; 95%CI: 0.37-0.93,P=0.024) (Tab 3). Similarly, subgroup analysis by the setting suggested lower odds of CIN with sodium bicarbonate in studies with patients undergoing emergency procedures (OR 0.16; 95%CI 0.05-0.51, P=0.002) (Tab 3). Before 2008, the effect of sodium bicarbonate was considered greater in articles reported(OR 0.19;95%CI:0.09-0.41,P<0.0001)(Tab 3). Furthermore, subgroup analysis according to the manner of sodium bicarbonate administration showed better effect in patients given bolus injection (OR 0.15; 95%CI 0.04-0.54, P=0.004) (Tab 3).Sodium

bicarbonate in combination with NAC showed a more salient efficacy in preventing CIN(OR 0.17;95%CI:0.04-0.79,P=0.024)(Tab 3).

Influence analysis showed no individual study had excessive influence on the overall estimate odds ratios and 95%CI(Fig 4).

Begg' funnel plot and Egger' test(P=0.396) implied no significant publication

Secondary Endpoints

Need for dialysis

The need for dialysis was described in a total of 17 studies(n=3,633). In eight of these studies, there was no dialysis event in both groups[11,12,15,16,18,19,22,24]. Overall, 14 out of 1,809 patients who treated with sodium bicarbonate underwent dialysis compared with 13 out of 1,824 patients treated with saline. No statistical significant difference was observed (OR 1.08; 95%CI 0.52-2.25, P=0.841) (Fig 3a), nonetheless, the OR for the requirement of dialysis suggested that maybe sodium bicarbonate was no better than saline in terms of reducing the dialysis events.

Mortality

Post-procedural death was described in a total of 12 studies(n=2,559), in six studies, there was no death in either group[11,13,14,16,23,24]. There were altogether 15 deaths in the 1,279 patients treated with sodium bicarbonate and 22 in the 1,280 patients treated with saline. Although there was no significant difference between the two arms (OR 0.69; 95%CI 0.36-1.32, P=0.263) (Fig 3b), a trend toward lower mortality risk occurred in sodium bicarbonate arm compared with saline arm.

Discussion

Although CIN is generally regarded as a transient decline in renal function after contrast procedures, it cannot be regarded as a benign complication[25,26]. It accounts for 12% of all cases of acute renal failure[27]. In a observational study, 0.8% of included patients undergoing coronary angiography or Interventional procedures

started dialysis and 13% of them needed a permanent one[28]. Furthermore, the development of CIN is associated with a longer hospital stay, an increased morbidity and mortality, in addition to a higher financial cost. Consequently, we can never be blind to the hazard of CIN.

Various risk factors may contribute to CIN, which are divided into two groups: patient- and procedure-related[29]. Preexisting renal insufficiency and diabetes mellitus are the two main patient- related risk factors. That is one reason why we focus on the patients with a history of renal insufficiency. Renal insufficiency was usually defined as a decrease in eGFR and since the eGFR has to be reduced by 50% before a rise in serum creatinine occurs, an elevated serum creatinine level was used as the cut-off point for the definition for renal insufficiency[21]. In a retrospective review of 938 patients with stable renal insufficiency, the overall incidence of CIN was 6.1%, and the incidence was 4.4%, 10.5%, 10.0% for patients whose eGFR was 45-60, 30-45, and ≤30ml/min, respectively[30]. Hence special care should be taken in patients with renal insufficiency.

In order to prevent CIN, sodium bicarbonate has been proposed by various mechanisms[31,32]. Namely, how does it work remains unknown. Some potential mechanisms are that alkalinizing the tubular urine with sodium bicarbonate may attenuate free radical formation and peroxide injury[28].Oxygen free radicals and peroxide usually generate in acidic conditions, infusion of sodium bicarbonate could increase the PH of local renal tissue to neutral or slightly alkaline, thereby reducing the production of free radicals and peroxide. Merten et al[19] first introduced the administration of sodium bicarbonate in a concentration of 154mmol/L to prevent CIN. In this study, hydration regimens of 13 trials [9-17,19-21,33] were performed similarly to "Merten protocol". Although most previous systematic reviews and relevant meta-analyses demonstrated that sodium bicarbonate infusion could decrease the incidence of CIN[25,26,34-42], secondary clinical endpoints as diverse

BMJ Open: first published as 10.1136/bmjopen-2014-006989 on 17 March 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES)

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

as renal replacement therapy and mortality were not ameliorated. Furthermore, a retrospective cohort study of 7,977 patients at Mayo Clinic got a surprising result: sodium bicarbonate was associated with an increased incidence of CIN[43]. By contrast with a majority of RCTs using creatinine elevations within 48-72h after contrast exposure to define CIN, From et al extended the definition time of CIN to a week based on the fact that creatinine may peak 3 to 7d after contrast. However, this issue remains to be discussed. Because in our study, all the patients with a history of renal insufficiency, the peak of serum creatinine may advance.

In this meta-analysis, underlying sources of moderate heterogeneity should be taken into account, because the study subjects, study settings and type of contrast media were varied. In this case, subgroup analyses were conducted and the results revealed significant differences between emergency and elective procedures, the protective role of sodium bicarbonate played better in the former than latter. In a meta-analysis[42] of the effect of sodium bicarbonate for the prevention of CIN, subgroup analyses also showed a more pronounced efficacy of sodium bicarbonate in 3 trials[18,33,44] included patients undergoing emergency procedures compared with those undergoing elective procedures. But the exact mechanism by which sodium bicarbonate results in a decrease incidence of CIN is still a mystery. Maybe it's related to manner of administration and dosage. Similarly, sodium bicarbonate was more beneficial in patients who received low-osmolar contrast agents[45,46]. However, because of the significantly smaller case number of included patients who received iso-osmolar contrast media (n=1,189) compared with those received low-osmolar ones(n=2,823), the major reason responsible for the more salient effect of sodium bicarbonate is difficult to elucidate.

Although the utilization of N-acetylcysteine(NAC) has been known to reduce the incidence of CIN and the value of it has been the focus of many studies, the definitive effect of NAC is not yet established. Not a few trials and meta-analyses indicated the

BMJ Open: first published as 10.1136/bmjopen-2014-006989 on 17 March 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES)

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

combination of sodium bicarbonate and NAC is superior to either regimen in preventing of CIN. Also, three studies[20,44,47] included patients who received NAC in both groups after the infusion of sodium bicarbonate or saline and the results were in favor of sodium bicarbonate. The BINARIO[48]study indicated that hydration with sodium bicarbonate in addition to high-dose NAC in the setting of urgent PCI for STEMI was associated with a net clinical benefit. However, Yang et al[27]and Thayssen et al [49]concluded that use of NAC caused no significant reduction in the incidence of CIN. In our study, because of only one trial[20]using NAC included in the sub-analyses, the effect of which may be overestimated (OR 0.17;95%CI 0.04-0.79, P=0.024). Accordingly, more large-scale and well-designed randomized clinical trials are warranted to determine whether sodium bicarbonate plus NAC is more useful in preventing CIN than either alone.

Many studies have now shown that patients with CIN have a greater risk for the renal replacement therapy and death. In fact, almost all the dialysis and death events occurred in patients with CIN who have high-risk factors. So we could not rely on sodium bicarbonate alone to improve the bad situations caused by CIN together with basic diseases, such as renal insufficiency, diabetes mellitus. Maybe that is one vital reason why we did not find a significant difference in both requirement of dialysis and mortality. However, the lack of power of included RCTs could also be attributed to. In this meta-analysis, not all studies described renal replacement therapy and mortality and sample sizes were relatively small. So this issue needs further research.

Conclusions

Our meta-analysis demonstrates the administration of sodium bicarbonate is superior to the administration of saline in the prevention of CIN in patients with preexisting renal insufficiency undergoing procedures requiring contrast media. However, the use of sodium bicarbonate did not result in clear benefit in regard to reductions in requirement of dialysis and mortality. Therefore, more large sample

BMJ Open

	do Lw
trials are required to detect the efficacy of sodium bicarbonate in preventing CIN and	MJ Open: first published as 10.1136/bmjopen-2014-006989 on 17 March 2015. Do Enseignemen Protected by copyright, including for uses related to
improving the clinical prognosis of patients with CIN.	st put
Footnotes	olishe
Contributors: B.Z, L.L and WB.C searched the studies. B.Z wrote the manuscript.	d as 1 F 1
L.L ,WB.C, CH.L and SX.Z reviewed, analyzed and helped writing the manuscript.	0.113 Protec
All authors contributed to the conception and design of this study.	6/bmj ted by
Funding: This study was supported by grants from National Scientific Foundation of	open-
China(No:81171329)and Guangdong Science Foundation(No: S2011010000790) .	2014- /right,
Competing interests: None.	00698 , inclu
Provenance and peer review: Not commissioned; externally peer reviewed.	10.1136/bmjopen-2014-006989 on 17 March Ens Protected by copyright, including for uses
Data sharing statement: No additional data are available.	17 Mai E for us
References	rch 20 nseig es rel
1 Golshahi J, Nasri H, Gharipour M, et al. Contrast-induced nephropathy; A literature	115. D. neme ated t
review[J]. J Nephropathol 2014; 3(2):51-6	ownlo o text
2Humbert A, Kissling S, Teta D. Contrast-induced nephropathy[J].Rev Med Suisse	Downloaded from http://bm lent Superieur (ABES) . I to text and data mining, Al
2013;9(389):1222-1228.	from rr (AB data rr
3 Mohammed NMA, Mahfouz A, Achkar K, et al. Contrast-induced nephropathy[J].	http:// ES) . 1ining
Heart views 2013; 14(3): 106-16.	
4 Silva RG, Silva NG, Lucchesi F, et al. Prevention of contrast-induced nephropathy by	jopen.bmj.com/ on June 13, 2025 a training, and similar technologies
use of bicarbonate solution: preliminary results and literature review[J].Jornal	mj.co y, and
Brasileiro de Nefrologia 2010;32(3): 292-302.	m∕ on simil
5 Weisbord SD, Chen H, Stone RA, et al. Associations of increases in serum creatinine	June ar tec
with mortality and length of hospital stay after coronary angiography[J]. JASN 2006;	13, 2 hnolo
17(10): 2871-2877.	025 at gies.
6 Subedi B, Siddique MA, Zaman SM, et al. Contrast induced nephropathy in patients	Ager
with pre-existing renal impairment undergoing coronary angiogram and	nce Bi
percutaneous transluminal coronary angioplasty[J]. Mymensingh medical journal	open.bmj.com/ on June 13, 2025 at Agence Bibliographique de training, and similar technologies.
	aphiq.
12 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	ue de
	_

ω

BMJ Open: first published as 10.1136/bmjopen-2014-006989 on 17 March 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES)

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

2011;20(2): 270-274.

7 Adolph E, Holdt-Lehmann B, Chatterjee T, et al. Renal Insufficiency Following Radiocontrast Exposure Trial (REINFORCE): a randomized comparison of sodium bicarbonate versus sodium chloride hydration for the prevention of contrast-induced nephropathy[J]. Coron Artery Dis 2008;19(6): 413-419.

8 Brar SS, Shen AY, Jorgensen M, et al. Sodium bicarbonate vs sodium chloride for the prevention of contrast medium–induced nephropathy in patients undergoing coronary angiography: a randomized trial[J]. Jama 2008;300(9): 1038-1046. 9 Maioli M, Toso A, Leoncini M, et al. Sodium bicarbonate versus saline for the prevention of contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention[J]. J Am Coll Cardio 2008; 52(8): 599-604.

10 Vasheghani-Farahani A, Sadigh G, Kassaian SE, et al. Sodium bicarbonate plus isotonic saline versus saline for prevention of contrast-induced nephropathy in patients undergoing coronary angiography: a randomized controlled trial[J]. Am J Kidney Dis 2009;54(4): 610-618.

11 Vasheghani-Farahani A, Sadigh G, Ebrahim Kassaian S, et al. Sodium bicarbonate in preventing contrast nephropathy in patients at risk for volume overload: a randomized controlled trial[J]. J Nephrol 2010; 23(2): 216.

12 Castini D, Lucreziotti S, Bosotti L, et al. Prevention of Contrast-induced
Nephropathy: A Single Center Randomized Study[J]. Clin Cardiol 2010;33(3): E63-E68.
13 Lee S W, Kim W J, Kim Y H, et al. Preventive strategies of renal insufficiency in patients with diabetes undergoing intervention or arteriography (the PREVENT Trial)[J]. Am J Cardiol 2011; 107(10): 1447-1452.

14 Hafiz AM, Jan MF, Mori N, et al. Prevention of contrast-induced acute kidney injury in patients with stable chronic renal disease undergoing elective percutaneous

1 2	
3 4	coronary and peripheral interventions: Randomized comparison of two preventive
5 6	strategies[J]. Catheter Cardiovasc Interv 2012;79(6): 929-937.
7 8	15 Gomes VO, Lasevitch R, Lima VC, et al. Hydration with sodium bicarbonate does
9 10	not prevent contrast nephropathy: a multicenter clinical trial[J]. Arq Bras Cardiol
11 12	2012;99(6): 1129-1134.
13 14	16 Boucek P, Havrdova T, Oliyarnyk O, et al. Prevention of contrast-induced
15 16	nephropathy in diabetic patients with impaired renal function: A randomized, double
17 18	blind trial of sodium bicarbonate versus sodium chloride-based hydration[J]. Diabetes
19 20	Res Clin Pract 2013; 101(3): 303-308.
20 21 22	17 Kristeller JL, Zavorsky GS, Prior JE, et al. Lack of effectiveness of sodium
22 23 24	bicarbonate in preventing kidney injury in patients undergoing cardiac surgery: a
25	
26 27	randomized controlled trial[J]. Pharmacotherapy 2013; 33(7): 710-717.
28 29	18 Ueda H, Yamada T, Masuda M, et al. Prevention of contrast-induced nephropathy
30	by bolus injection of sodium bicarbonate in patients with chronic kidney disease
31 32	undergoing emergent coronary procedures[J]. Am J Cardiol 2011;107(8): 1163-1167.
33 34	19 Merten GJ, Burgess WP, Rittase RA, et al. Prevention of contrast-induced
35 36	nephropathy with sodium bicarbonate: an evidence-based protocol[J]. Crit Pathw
37 38	Cardiol 2004;3(3): 138-143.
39 40	20 Briguori C, Airoldi F, D'Andrea D, et al. Renal Insufficiency following contrast media
41 42	administration trial (REMEDIAL) A randomized comparison of 3 preventive strategies
43 44	[J]. Circulation 2007; 115(10): 1211-1217.
45	
46 47	21 Klima T, Christ A, Marana I, et al. Sodium chloride vs. sodium bicarbonate for the
48 49	prevention of contrast medium-induced nephropathy: a randomized controlled
50 51	trial[J]. Eur Heart J 2012;33(16): 2071-2079.
52 53	22 Kooiman J, Sijpkens YW, de Vries JP, et al. A randomized comparison of 1-h sodium
54 55	bicarbonate hydration versus standard peri-procedural saline hydration in patients
56	
57 58	
59 60	14

BMJ Open: first published as 10.1136/bmjopen-2014-006989 on 17 March 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) .

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

with chronic kidney disease undergoing intravenous contrast-enhanced computerized tomography[J]. Nephrol Dial Transplant 2014; 29(5):1029-36.

23 Tamura A, Goto Y, Miyamoto K, et al. Efficacy of single-bolus administration of sodium bicarbonate to prevent contrast-induced nephropathy in patients with mild renal insufficiency undergoing an elective coronary procedure[J]. Am J Cardiol 2009;104(7): 921-925.

24 Motohiro M, Kamihata H, Tsujimoto S, et al. A new protocol using sodium bicarbonate for the prevention of contrast-induced nephropathy in patients undergoing coronary angiography[J]. Am J Cardiol 2011; 107(11): 1604-1608. 25 Meier P, Ko DT, Tamura A, et al. Sodium bicarbonate-based hydration prevents contrast-induced nephropathy: a meta-analysis[J]. BMC Med 2009; 7(1): 23. 26 Trivedi H, Nadella R, Szabo A. Hydration with sodium bicarbonate for the prevention of contrast-induced nephropathy: a meta-analysis of randomized controlled trials[J].Clin Nephrol 2010;74(4):288-296.

27 Yang K,Liu W, Ren W, et al. Different interventions in preventing contrast-induced nephropathy after percutaneous coronary intervention[J]. Int Urol Nephrol 2014;46 (9):1801-7.

28 Atkins JL. Effect of sodium bicarbonate preloading on ischemic renal failure. Nephron 1986;44(1):70-74.

29 Andreucci, Michele, Richard Solomon, et al. Side Effects of Radiographic Contrast Media: Pathogenesis, Risk Factors, and Prevention[J].Biomed Res Int 2014;2014:

30 Murakami R, Hayashi H, Sugizaki K, et al. Contrast-induced nephropathy in patients with renal insufficiency undergoing contrast-enhanced MDCT[J]. Eur Radiol 2012; 22(10): 2147-2152.

31 McCullough PA, Adam A, Becker CR, et al. Risk prediction of contrast-induced nephropathy[J]. Am J Cardiol 2006;98(6): 27-36.

BMJ Open

32 Burgess WP, Walker PJ. Mechanisms of Contrast-Induced Nephropathy Reduction
for Saline (NaCl) and Sodium Bicarbonate (NaHCO3)[J]. Biomed Res Int 2014;2014:
510385
33 Masuda M, Yamada T, Mine T, et al. Comparison of usefulness of sodium
bicarbonate versus sodium chloride to prevent contrast-induced nephropathy in
patients undergoing an emergent coronary procedure[J]. Am J Cardiol 2007;100(5):
781-786.
34 Hogan SE, L'Allier P, Chetcuti S, et al. Current role of sodium bicarbonate-based
preprocedural hydration for the prevention of contrast-induced acute kidney injury: A
meta-analysis[J]. Am Heart J 2008;156(3): 414-421.
35 Joannidis M,Schmid M, Wiedermann CJ. Prevention of contrast media-induced
nephropathy by isotonic sodium bicarbonate: a meta-analysis[J].Wien Klin
Wochenschr 2008;120(23-24):742-8
36 Ho KM, Morgan DJ. Use of isotonic sodium bicarbonate to prevent radiocontrast
nephropathy in patients with mild pre-existing renal impairment: a meta-analysis
[J].Anaesth Intensive Care 2008;36(5): 646-653.
37 Navaneethan SD, Singh S, Appasamy S, et al. Sodium bicarbonate therapy for
prevention of contrast-induced nephropathy: a systematic review and meta-analysis
[J]. Am J Kidney Dis 2009;53(4): 617-627.
38 Brar SS, Hiremath S, Dangas G, et al. Sodium bicarbonate for the prevention of
contrast induced-acute kidney injury: a systematic review and meta-analysis[J].
Clinical Journal of the American Society of Nephrology 2009; 4(10): 1584-1592.
39 Kanbay M, Covic A, Coca SG, et al. Sodium bicarbonate for the prevention of
contrast-induced nephropathy: a meta-analysis of 17 randomized trials[J]. Int Urol
Nephrol 2009;41(3): 617-627.
40 Hoste EA, De Waele JJ, Gevaert SA, et al. Sodium bicarbonate for prevention of
contrast-induced acute kidney injury: a systematic review and meta-analysis[J].

BMJ Open: first published as 10.1136/bmjopen-2014-006989 on 17 March 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) .

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

BMJ Open

Nephrology Dialysis Transplantation 2010;25(3): 747-758.

41 Kunadian V, Zaman A, Spyridopoulos I, et al. Sodium bicarbonate for the prevention of contrast induced nephropathy: a meta-analysis of published clinical trials[J]. Eur J Radiol 2011;79(1): 48-55.

42 Jang JS, Jin HY, Seo JS, et al. Sodium bicarbonate therapy for the prevention of contrast-induced acute kidney injury–a systematic review and meta-analysis[J]. Circ J 2011; 76(9): 2255-2265.

43 From AM, Bartholmai BJ, Williams AW, et al. Sodium bicarbonate is associated with an increased incidence of contrast nephropathy: a retrospective cohort study of 7977 patients at Mayo Clinic[J]. Clinical Journal of the American Society of Nephrology 2008;3(1): 10-18.

44 Recio-Mayoral A, Chaparro M, Prado B, et al. The reno-protective effect of hydration with sodium bicarbonate plus N-acetylcysteine in patients undergoing emergency percutaneous coronary intervention: the RENO Study[J]. J Am Coll Cardiol 2007;49(12): 1283-1288.

45 Jo SH, Youn TJ, Koo BK, et al. Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial[J]. J Am Coll Cardiol 2006; 48(5): 924-930.

46 McCullough PA, Bertrand ME, Brinker JA, et al. A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media[J]. J Am Coll Cardiol 2006;48(4): 692-699.

47 Mahmoodi K, Sohrabi B, Ilkhchooyi F, et al. The efficacy of hydration with normal saline versus hydration with sodium bicarbonate in the prevention of contrast-induced nephropathy[J]. Heart views 2014; 15(2): 33.

48 Leone AM, De Caterina AR, Sciahbasi A, et al. Sodium bicarbonate plus N-acetylcysteine to prevent contrast-induced nephropathy in primary and rescue

percutaneous coronary interventions: the BINARIO (BIcarbonato e N-Acetil-cisteina nell'infaRto mIocardico acutO) study[J].EuroIntervention, 2012; 8(7): 839-847.

49 Thayssen P, Lassen JF, Jensen SE, et al. Prevention of Contrast-Induced Nephropathy With N-Acetylcysteine or Sodium Bicarbonate in Patients With ST-Segment–Myocardial Infarction A Prospective, Randomized, Open-Labeled Trial[J]. Circ Cardiovasc Interv 2014;7(2): 216-224.

Table and figure legends:

Table 1: The baseline characteristics of included studies

Table 2: Quality assessment of included studies

Table 3:Subgroup analyses: to assess the effect of sodium bicarbonate in various conditions

Figure 1: Selecting flow chart showing the number of excluded trials and the reasons,

BMJ Open: first published as 10.1136/bmjopen-2014-006989 on 17 March 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) .

data mining, AI training, and similar technologies

Protected by copyright, including for uses related to text and

As well as the number of included trials

Figure 2: The forest plot of odds ratios of contrast induced nephropathy

Figure 3a: Need for dialysis

Figure 3b: Mortality

Figure 4: The influence of an individual study on the overall estimates

Figure 5: Funnel plot with pseudo 95% confidence limits

-	
2	
3	
4	
4	
5	
5 4 5 6 7	
0	
7	
8	
0	
9	
1	0
	Ă
	T
1	2
1	2
I	S
1	4
1	5
	2
1	6
1	0123456789010
	0
1	Ø
1	9
n	\cap
2	Ú
2	1
2	2
~	~
2	3
2	4
5	234567890123456789
2	Э
2	6
2	7
~	'
2	8
2	9
~	2
3	0
3	1
2	s S
3	Ζ
3	3
ર	Δ
2	-
3	5
3	6
2	-
3	1
3	8
2	a
	3
4	
4	1
- 7	<u>.</u>
4	2
4	3
4	Ā
4	4
4	5
4	6
1	2
4 4	1
4	8
, ,	0901234567
4	Э
5	0
5	1
0	1
5	2
5	3
-	~
5	4
5	5
F	é
Э	0
- ^	1
5 5	8
5	0
5	9
6	0
5	-

Tab 1 The baseline characteristics of included studies

Church Car		Age(years)	ears)	DM		HT Baseline S		cr(mg/dl)	eGFR(ml/min/1.73m ²)	
Study	Study Cases Bicarbonate Saline		- Male(%)	%	%	Bicarbonate	Saline	Bicarbonate	Saline	
Merten	119	66.7*	69.2*	73/76	50/46	NA	1.89*	1.71*	41.0*	45.0*
Ozcan	176	68.0*	70.0*	76/75	42/48	75/81	1.36*	1.40*	NA	NA
Masuda	59	75.0±8.0	76.0±11.0	63/59	27/35	NA	1.31±0.52	1.32±0.65	40.2±15.4	38.7±15.
REMEDIAL	219	70.0±9.0	71.0±9.0	88/81	49/55	92/87	2.04*	1.95*	32.0±7.0	71.0±9.0
Adolph	145	70.1±8.4	72.7±6.6	75/81	37/28	83/91	1.54±0.51	1.57±0.36	NA	NA
Brar	323	71.0*	71.0*	62/65	43/46	NA	1.49#	1.49#	47.7#	48.3#
Maioli	502	74.0*	74.0*	57/61	25/23	59/57	1.21±0.30	1.20±0.30	NA	NA
Tamura	144	72.3±9.9	73.3±7.7	92/83	60/57	85/83	1.36±0.18	1.38±0.19	40.0±7.5	38.2±0.2
Vasheghani	265	62.9±10.0	63.8±9.0	84/82	22/21	30/41	1.63±0.32	1.66±0.50	46.4±12.0	45.4±12
Castini	103	70.0±8.3	72.7±8.2	85/84	35/20	71/78	1.59±0.38	1.49±0.30	46.9±12.8	49.9±10
Vasheghani(2)	72	61.4#	62.7#	78/81	33/38	66/71	1.77#	1.71#	42.7#	44.2#
Motohiro	155	71.0±9.0	74.0±7.0	76/64	56/63	86/83	1.54±0.43	1.55±0.44	45.7±12.9	42.8±13
PREVENT	382	65.8*	67.5*	71/71	100/100	77/80	1.50*	1.50*	46.0*	46.0*
Ueda	59	77.0±9.0	75.0±10.0	77/79	10/10	NA	1.32±0.46	1.51±0.59	42.4±11.5	38.7±12
Klima	176	78.0*	75.0*	66/62	39/34	90/81	1.60*	1.60*	43.1#	43.0#
Gomes	301	64.1±12.0	64.5±12.0	15/75	29/30	77/74	1.50±0.40	1.49±0.50	50.5±13.0	51.9±13
Hafiz	320	74.0*	73.0*	57/57	49/45	95/94	1.65*	1.60*	41.5*	40.5*
Kristeller	92	72.0±11.0	73.0±11.0	64/52	52/38	89/92	NA	NA	48.9#	49.4#
Boucek	120	63.0#	67.0#	75/75	NA	NA	1.92#	1.81#	43.6#	44.6#
Kooiman	548	71.6#	72.5#	60/61	27/27	NA	NA	NA	49.9#	50.9#

Note: DM=diabetes mellitus HT=hypertension eGFR=estimated glomerular filtration rate NA= not applicable

*median value #mean value

BMJ Open: first published as 10.1136/bmjopen-2014-006989 on 17 March 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Tab 1 Continued

Dresedure	Interventions	Contrast type and Volume(ml)			Definition of CIN	
Procedure	Interventions	Bicarbonate Saline		 Hydration regimen 		
Elective diagnostic /interventional procedures	SB vs SC	NA Iopamidol,nonior	NA nic,Low-osmolar	3ml·kg ⁻¹ ·h ⁻¹ for 1h before and 1ml·kg ⁻¹ ·h ⁻¹ for 6h after the procedure of SB or SC	Scr个≥25% within 2	
Elective CAG/PCI	SB vs SC	100* loxaglate,ionic,	100* Low-osmolar	1ml·kg ⁻¹ ·h ⁻¹ for 6h before and after the procedure of SB or SC	Scr个>0.5mg/dl or 25% within 2d	
Emergency CAG/PCI	SB vs SC	112±89 Iopamidol,nonior	120±61 nic,Low-osmolar	3ml·kg ⁻¹ ·h ⁻¹ for 1h before and 1ml·kg ⁻¹ ·h ⁻¹ for 6h after the procedure of SB or SC	Scr个>0.5mg/dl or 25% within 2d	
Elective CAG/ PCI /peripheral procedure	SB+NAC vs NS+NAC	169±92 Iodixanol,nonion	179±9 nic,Iso- osmolar	3ml·kg ⁻¹ ·h ⁻¹ for 1h before and 1ml·kg ⁻¹ ·h ⁻¹ for 6h after:SB; 1ml·kg ⁻¹ ·h ⁻¹ for 12h before and 12h after:NS	Scr个≥25% within 2	
Elective CAG/PCI	SB vs SC	141±50 Iodixanol,nonion	138±52 nic,Iso- osmolar	2ml·kg ⁻¹ ·h ⁻¹ for 2h before and 1ml·kg ⁻¹ ·h ⁻¹ for 6h after the procedure of SB or SC	Scr个>0.5mg/dl or 25% within 2d	
Elective CAG	SB vs SC	126* Ioxilan,nonionio	137* c,Iso- osmolar	$3ml\cdot kg^{-1}\cdot h^{-1}$ for 1h before and $1.5ml\cdot kg^{-1}\cdot h^{-1}$ for 4h after the procedure of SB or SC	eGFR↓>25% withir 4d	
Elective CAG/PCI	SB vs IS	160* Iodixanol,nonion	170* nic,Iso- osmolar	$3ml\cdot kg^{-1}\cdot h^{-1}$ for 1h before and $1ml\cdot kg^{-1}\cdot h^{-1}$ for 6h after:SB; $1ml\cdot kg^{-1}\cdot h^{-1}$ for 12h after:IS	Scr个≥0.5mg/dl within 5d	
Elective CAG/PCI	Bolus SB+SC vs SC	82±40 Iohexol,nonionio	88±45 c,Low-osmolar	Single-bolus SB 20ml for 5min before and SC 1ml·kg ⁻¹ ·h ⁻¹ for 12h pre- and post- procedure; 1ml·kg ⁻¹ ·h ⁻¹ for 12h pre- and post-procedure of SC	Scr个>0.5mg/dl or 25% within 3d	
Elective CAG	SB+Is vs IS	115±41 Iohexl,nonionic	113.2±36 c,Low-osmolar	3ml·kg ⁻¹ ·h ⁻¹ for 1h before and 1ml·kg ⁻¹ ·h ⁻¹ for 6h after in both groups	Scr个≥0.5mg/dl or 25% within 2d	
Elective CAG/PCI	SB vs SC	179±125 Iodixanol,nonion	196±128 ic,Low-osmolar	$3ml \cdot kg^{-1} \cdot h^{-1}$ for 1h before and $1ml \cdot kg^{-1} \cdot h^{-1}$ for 6h after:SB; $1ml \cdot kg^{-1} \cdot h^{-1}$ for 12h before and after:SC	Scr个≥25% within 5	
Note: CAG=corona IS=isotonic s		PCI=percutaneou	-		um chloride	

Page 50 of 56

BMJ Open: first published as 10.1136/bmjopen-2014-006989 on 17 March 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Tab 1 Continued

Drocoduro	Interventions –	Contrast type and Volume(ml)		Hudratian ragiman	Definition of CIN	
Procedure	interventions –	Bicarbonate Saline		 Hydration regimen 		
Elective CAG	e CAG vs half SC Low-osmolar		3ml·kg ⁻¹ ·h ⁻¹ for 1h before and 1ml·kg ⁻¹ ·h ⁻¹ for 6h after the procedure of 75ml SB to1L of 0.45%SC; 1075ml 0.45%SC	Scr个≥0.5mg/dl or 25% within 2d		
Elective CAG/PCI	SB+SC vs SC	140±50 Iopamidol, I Low-osr		$1 \text{ml} \cdot \text{kg}^{-1} \cdot \text{h}^{-1} \text{ SC 12h before and } 1 \text{ml} \cdot \text{kg}^{-1} \cdot \text{h}^{-1}$ SB from 3h pre-to 6h post-procedure, then 1 \text{ml} \cdot \text{kg}^{-1} \cdot \text{h}^{-1} \text{ SC for 12h; } 1 \text{ml} \cdot \text{kg}^{-1} \cdot \text{h}^{-1} SC 12h pre- and 12h post- procedure	Scr个≥0.5mg/dl or>25% within 2d	
Elective CAG/ angioplasty/ endovascular intervention	SB vs SC	113* Iodixanol,n Low-osr		3ml·kg ⁻¹ ·h ⁻¹ for 1h before and 1ml·kg ⁻¹ ·h ⁻¹ for 6h after:SB; 1ml·kg ⁻¹ ·h ⁻¹ for 12h:SC	Scr个≥0.5mg/dl or>25% within 2d	
Emergency CAG/ PCI	SB vs SC	116±63 Iopamidol/ Low-osr		Bolus 0.5mg/ml SB before and SC 1ml·kg ⁻¹ ·h ⁻¹ for 6h during and after in both groups	Scr个≥0.5mg/dl or >25% within 2d	
Elective CAG/ PCI/ PTA/CT/ PAG	SB vs SC	100* Iopromide/ic Iso/Low-c		3ml·kg ⁻¹ ·h ⁻¹ for 1h before and 1ml·kg ⁻¹ ·h ⁻¹ for 6h after:SB; 1ml·kg ⁻¹ ·h ⁻¹ for 24h:SC	Scr个≥0.5mg/dl or 25% within 2d	
Elective CAG/PCI	SB vs NS	124±65 Hexabrix/Lo Low-osr	-	3ml·kg ⁻¹ ·h ⁻¹ for 1h before and 1ml·kg ⁻¹ ·h ⁻¹ for 6h after the procedure of SB or NS	Scr个≥0.5mg/dl within 2d	
Elective CAG/ PAG/ intervention	SB±NAC vs NS±NAC	110* Iodixanol/Iopam nonionic,Lov		3ml·kg ⁻¹ ·h ⁻¹ for 1h before and 1ml·kg ⁻¹ ·h ⁻¹ for 6h after:SB; 1ml·kg ⁻¹ ·h ⁻¹ for 12h before and 12h after:NS	Scr个>0.5mg/dl or 25% within 2d	
Elective CPB	SB vs IS	74# NA	83#	3ml·kg ⁻¹ ·h ⁻¹ for 1h before and 1ml·kg ⁻¹ ·h ⁻¹ for 6h after the procedure of SB or IS	Scr↑≥0.3mg/dl or 50% or Urine outpu <0.5ml·kg ⁻¹ ·h ⁻¹ (>6h) within 5d	
Elective CAG/ Lower-limb angiography and /or angioplasty	SB vs NS	115# Iodinated,n Iow-osr		3ml·kg ⁻¹ ·h ⁻¹ for 1h before and 1ml·kg ⁻¹ ·h ⁻¹ for 6h after the procedure of SB or SC	Scr个≥0.5mg/dl or 25% within 2d	
Elective CECT	SB vs IS	105.7# Iomeprol/Ic Iodixanol,Lov		250ml SB for 1h before; 1000ml IS before and 1000ml IS after	Scr↑>0.5mg/dl or 25% within 4d	

Tab 2 Quality assessment of included studies


	Trial described	Randomized	Allocation	Allocation	Trial described	Double blind	Withdrawals	
Included	as randomized	method	concealment	concealment	as double	method	& Dropouts	Jadad
trials	(1=yes, 0=no)	described &	described ⁺	described &	blind	described &	described	score *
LI Idis		appropriate	(1=yes, 0=no)	appropriate	(1=yes, 0=no)	appropriate	(1=yes,0=no)	score
		(1=yes, 0=no)		(1=yes, 0=no)		(1=yes,0=no)		
Merten	1	1	0	0	0	0	1	4
Ozcan	1	0	0	0	0	0	1	2
Masuda	1		0	0	0	0	1	4
REMEDIAL	1	1	0	0	1	0	1	5
Adolph	1	1	0	0	1	0	1	5
Brar	1	1	1	1	0	0	1	5
Maioli	1	1	1	1	0	0	0	4
Tamura	1	1	0	0	0	0	1	4
Vasheghani	1	1	0	0	1	0	0	4
Castini	1	1	0	0	0	0	0	3
Vasheghani(2)	1	1	0	0	1	0	0	4
Motohiro	1	1	0	0	0	0	1	4
PREVENT	1	1	0	0	0	0	1	4
Ueda	1	1	0	0	0	0	0	3
Klima	1	0	1	1	0	0	0	3
Gomes	1	0	1	1	0	0	0	3
Hafiz	1	1	0	0	0	0	1	4
Kristeller	1	1	1	1	1	0	0	5
Boucek	1	1	1	1	1	0	1	6
Kooiman	1	1	0	0	0	0	1	4


Note: †One point can be obtained from Jadad Score if randomization method of the trial is described & appropriate


*Calculation for quality assessment of included trials:low,1-3;high,4-7


Tab 3 Subgroup analyses: to assess the effect of sodium bicarbonate in various co	onditions
---	-----------

Subgroups	Trials/patients	OR(95%CI)	Test for overall effect	Heterogeneity
Type of contrast				
Low-osmolar	14/2823	0.59[0.37,0.93]	Z=2.26(P=0.024)	X ² =26.61,df=13(P=0.014),l ² =51%
lso-osmolar	4/1189	0.76[0.43,1.34]	Z=0.93(P=0.351)	X ² =4.67, df=3(P=0.198),I ² =36%
Setting				
Elective	18/4162	0.76[0.54,1.06]	Z=1.62(P=0.105)	X ² =29.54,df=17(P=0.030),l ² =43%
Emergency	2/118	0.16[0.05,0.51]	Z=3.11(P=0.002)	X ² =0.07,df=1(P=0.784),I ² =0%
Using NAC or not				
Use	1/219	0.17[0.04,0.79]	Z=2.26(P=0.024)	Not applicable
Non-use	18/3741	0.71[0.48,1.03]	Z=1.80(P=0.071)	X ² =33.13,df=17(P=0.011),l ² =49%
Publication year				
Before 2008	4/573	0.19[0.09,0.41]	Z=4.26(P=0.000)	X ² =1.06,df=10(P=0.788),l ² =0%
After 2008	16/3707	0.85[0.62,1.16]	Z=1.03(P=0.302)	X ² =22.13,df=15(P=0.105),l ² =32%
Manner of adminis	stration			
Continuous	18/4077	0.75[0.53,1.05]	Z=1.69(P=0.091)	X ² =30.21,df=17(P=0.025),l ² =44%
Bolus	2/203	0.15[0.04,0.54]	Z=2.90(P=0.004)	X ² =0.23,df=1(P=0.632),l ² =0%










BMJ Open: first published as 10.1136/bmjopen-2014-006989 on 17 March 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES). Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml








Fig 4 The influence of an individual study on the overall estimates.





BMJ Open

The efficacy of sodium bicarbonate preventing contrastinduced nephropathy in patients with preexisting renal insufficiency: a meta-analysis

Journal:	BMJ Open
Manuscript ID:	bmjopen-2014-006989.R1
Article Type:	Research
Date Submitted by the Author:	28-Jan-2015
Complete List of Authors:	Zhang, Bin; 1.Southern Medical University;2.Guangdong General Hospital, Radiology Liang, Long; 1.Southern Medical University;2.Guangdong General Hospital, Radiology Chen, WB; Guangdong General Hospital, Radiology Liang, CH; Guangdong General Hospital, Radiology Zhang, SX; Guangdong General Hospital, Radiology
Primary Subject Heading :	Radiology and imaging
Secondary Subject Heading:	Global health, Renal medicine, Public health, Evidence based practice
Keywords:	Dialysis < NEPHROLOGY, Chronic renal failure < NEPHROLOGY, Acute renal failure < NEPHROLOGY



The efficacy of sodium bicarbonate preventing contrast-induced nephropathy in patients with preexisting renal insufficiency: a meta-analysis

Bin Zhang^{1, 2}, Long Liang^{1, 2}, Wenbo Chen², Changhong Liang², Shuixing Zhang^{2*}.

¹Graduate College, Southern Medical University, 510515 Guangzhou, China ²Department of Radiology, Guangdong Academy of Medical Sciences/Guangdong General Hospital, No. 106 Zhongshan Er Road, 510080 Guangzhou, Guangdong Province, China

*Corresponding author: Shuixing Zhang, Department of Radiology, Guangdong

Academy of Medical Sciences/Guangdong General Hospital, No. 106 Zhongshan Er

BMJ Open: first published as 10.1136/bmjopen-2014-006989 on 17 March 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES)

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

Road, 510080 Guangzhou, Guangdong Province, China

E-mail: shui7515@hotmail.com

Tel: +86 20 83870125 Fax: +86 20 83870125

Key words: Sodium bicarbonate; Saline; Contrast-induced nephropathy;

Renal insufficiency; Meta-analysis

Text word count: 3, 010

BMJ Open: first published as 10.1136/bmjopen-2014-006989 on 17 March 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Abstract

Objective: The aim of this meta-analysis was to explore the efficacy of sodium bicarbonate in preventing contrast-induced nephropathy (CIN) and assess if it could reduce the risks of dialysis and mortality to improve the clinical prognosis of patients with CIN.

Methods: We searched PubMed, Medline and the Cochrane Library from January 1, 2004 to August 1, 2014. The effect estimate was expressed as pooled odds ratio (OR) with 95% confidence interval (CI), using the fixed effects model or random effects model.

Results: 20 randomized controlled trials (RCT) (n=4, 280) were identified. Hydration with sodium bicarbonate was associated with a significant decrease in the incidence of CIN among patients with preexisting renal insufficiency (OR 0.67; 95%CI: 0.47-0.96; P=0.027). However, moderate heterogeneity was noted across trials ($I^2=48\%$; P=0.008). Therefore, we performed subgroup analyses and indicated a better effect of sodium bicarbonate in studies using low-osmolar contrast agents (OR 0.59; 95%CI: 0.37-0.93, P=0.024) compared with those using iso-smaller ones (OR 0.76; 95%CI: 0.43-1.34, P=0.351). A lower odds of CIN with sodium bicarbonate occurred in studies including exclusively patients undergoing emergency procedures (OR 0.16; 95%CI: 0.54-1.06, P=0.002) compared with those undergoing elective ones (OR 0.76; 95%CI: 0.54-1.06, P=0.105). Sodium bicarbonate played a more beneficial role in patients given a bolus injection before procedures (OR 0.15; 95%CI: 0.04-0.54, P=0.004) compared with continuous infusion (OR 0.75; 95%CI: 0.53-1.05, P=0.091).

BMJ Open

Sodium bicarbonate plus N-acetylcysteine (NAC) (OR 0.17; 95%CI: 0.04-0.79, P= 0.024) outweighed sodium bicarbonate alone (OR 0.71; 95%CI: 0.48-1.03, P=0. 071). The effect of sodium bicarbonate was considered greater in papers published pre-2008 (OR 0.19; 95%CI: 0.09-0.41, P=0. 000) than post-2008 (OR 0.85; 95%CI: 0.62-1.16, P=0. 302). However, no significant differences were found in the mortality (OR 0.69; 95%CI: 0.36-1.32, P=0. 263) and the requirement for dialysis (OR 1.08; 95%CI: 0.52-2.25, P=0. 841).

Conclusions: Sodium bicarbonate is effective in preventing CIN among patients with preexisting renal insufficiency. However, it failures to lower the risks of dialysis and mortality and therefore cannot improve the clinical prognosis of patients with CIN.

Article summary

Article focus:

• To explore the efficacy of sodium bicarbonate in preventing contrast-induced nephropathy.

• To assess if sodium bicarbonate could reduce the risks of dialysis and mortality to improve the clinical prognosis of patients with CIN.

Key messages:

• Sodium bicarbonate is effective in preventing CIN among patients with preexisting renal insufficiency.

• Infusion of sodium bicarbonate failures to lower the risks of dialysis and mortality.

Strengths and limitations of this study

• In this updated meta-analysis, we demonstrated that pre-procedural hydration with

sodium bicarbonate was associated with a significant decrease in the incidence of CIN among patients with preexisting renal insufficiency.

• In this study, we found that sodium bicarbonate couldn't lower the risks of dialysis and mortality to improve the clinical prognosis of patients with CIN.

• New Jadad Scale after the revision was used to assess the quality of articles.

• No publication bias.

• However, moderate heterogeneity was noted among the included trials.

Keywords: Sodium bicarbonate; Saline; Contrast-induced nephropathy;

Renal insufficiency; Meta-analysis

Introduction

Contrast-induced nephropathy is the third leading cause of in-hospital acute kidney injury [1-3], which is a serious complication of angiographic procedures resulting from the administration of contrast media. Although the definition of CIN is various, CIN is usually defined as an increase in serum creatinine (Scr) level of 25% or an increase of 0.5 mg/dl (or 44 μ mol/L) from baseline within 48-72 hours of contrast exposure. It results in increased morbidity, prolonged hospital stay, and increased healthcare expenditure and is associated with a higher mortality [4].

The incidence of CIN in the general population is low, but increases exponentially in patients with high-risk factors, such as preexisting renal insufficiency, diabetes mellitus [5]. In a recent study, 21.7% of preexisting chronic renal insufficiency group and 6.3% of no preexisting chronic renal insufficiency group developed CIN [6]. Thus, baseline renal insufficiency may be a significant predisposing factor of CIN.

BMJ Open

To prevent CIN, sodium bicarbonate-based hydration has been proposed as one of the feasible therapies. According to recent studies, some of them suggested sodium bicarbonate elicited more protective effect compared with sodium chloride for the prevention of CIN, but others did not [7-17]. Although most previous meta analyses were on the side of sodium bicarbonate with possible publication bias, none of them focused on the patients with preexisting renal insufficiency. Therefore, we performed this meta-analysis to determine the efficacy of sodium bicarbonate in preventing of contrast-induced nephropathy among patients with renal insufficiency undergoing procedures needing contrast agents. What's more, differences in the requirement for dialysis and post-procedural death between two groups were compared in this study as well.

Methods

Data sources and searches

We searched PubMed, Medline, and the Cochrane Library from January 1, 2004 to August 1, 2014 without language limitations. Medical subject headings and keyword searches included the terms "contrast induced nephropathy", "sodium bicarbonate", "sodium chloride", "saline", "acute kidney injury", "renal failure". Reference lists of selected articles were reviewed for other potentially relevant citations. In addition, top 50 citations for each identified relevant study were searched by using the "related articles" function of PubMed. BMJ Open: first published as 10.1136/bmjopen-2014-006989 on 17 March 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) .

data mining, AI training, and similar technologies

Protected by copyright, including for uses related to text and

Study selection

First, two investigators (B.Z and L.L) independently reviewed the titles and abstracts

of all studies to identify all potentially ones. Second, the online publications obtained from preliminary selection were reviewed in full text to assess if studies met the following inclusion criteria:

1) Participants: adult patients (\geq 18 years) with preexisting renal insufficiency, defined as a serum creatinine concentration of >1.1 mg/dl or estimated glomerular filtration rate (eGFR)<60 ml/min [18] or creatinine clearance rate<60 ml/min [9].

Comparison: sodium bicarbonate (and/or N-acetylcysteine) versus saline (and/or N-acetylcysteine).

3) Outcome: the primary outcome of this study is the incidence of CIN, the secondary outcomes include the requirement for dialysis and the mortality.

4) Type of study: only RCT.

Reviewers were not blinded to study authors or outcomes. Final inclusion of studies was based on the agreement of both reviewers.

Exclusion criteria: insufficient data to extract, using N-acetylcysteine in only one arm.

Data extraction and quality assessment

Two independent reviewers (B.Z and WB. C) extracted relevant information from the literatures including baseline clinical characteristics (mean age, the percentage of males, risk factors other than renal insufficiency, baseline Scr, eGFR, procedures, interventions, type and volume of contrast media, hydration regimen, definition of CIN) (Table 1), data on primary (the incidence of CIN) and secondary outcomes (i.e., the requirement for dialysis and the mortality). CIN was defined variously in studies, but most of them described it as an absolute or relative increase in the level of serum

creatinine. 3 studies defined CIN as a rise in serum creatinine by 25% or more within 2-5 days of contrast exposure [12,19,20]. 13 studies regarded an increase of 0.5 mg/dl or 25% in Scr within 2-4 days of contrast as CIN. 2 studies considered an elevated Scr of 0.5 mg/dl after the procedures [9,15]. However, the remaining 2 trials were different from all above, a decrease in eGFR of 25% within 4 days and an absolute increase in Scr of at least 0.3 mg/dl or 50% or Urine output <0.5 ml·kg⁻¹·h⁻¹ (>6 h) within 5 days were used to define CIN, respectively [8,17]. We assessed the quality of articles using the New Jadad Scale after the revision (Table 2).

Data synthesis and analysis

Data from included studies were combined and expressed as pooled OR with 95%CI. All analyses were performed on an "intention-to-treat" basis. Initially, fixed -effects model (Mantel-Haenzel method) was used in this meta-analysis. We evaluated the heterogeneity across studies with the Cochrane's Q test and I² statistics. If the *P* value <0.10, statistically significant heterogeneity was considered. The I² statistic was used to quantify the magnitude of heterogeneity, with values of 0-30%, 31-50% and greater than 50% representing mild, moderate and substantial heterogeneity, respectively. The outcome of fixed-effects model analysis demonstrated a statistical heterogeneity, so we selected the random-effects model (Dersimonian and Laird method). BMJ Open: first published as 10.1136/bmjopen-2014-006989 on 17 March 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Considering of the clinical and statistical heterogeneity across studies, subgroup analyses using random effects model were performed to assess the effect of sodium bicarbonate in various conditions, such as low-osmolar vs. iso-osmolar contrast agent, emergency vs. elective procedures, the articles published pre- vs. post-2008, and

BMJ Open: first published as 10.1136/bmjopen-2014-006989 on 17 March 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

continuous vs. bolus infusion of sodium bicarbonate (Table 3). An influence analysis was carried out to evaluate how robust the pooled estimator was after the removal of an individual study at a time (Figure 4). An individual study is suspected of excessive influence if the point estimate of its omitted analysis lies outside the 95%CI of the summary analysis. Publication bias was assessed using Begg' funnel plot and Egger' regression asymmetry test (Figure 5). All statistical analyses were performed using STATA software, version 12.0 (Stata Corp LP, College Station, Texas). **Results**A total of 837 articles were reviewed and 20 studies reached the inclusion criteria were absorbed into this study finally (Figure 1). A detailed description of the baseline characteristics of the included studies

Was given in Table 1. Patients in most studies underwent coronary angiography or interventional procedures. There were also 7 studies examined peripheral procedures, angioplasty, cardiopulmonary bypass and computed tomography (CT) [8,18,19,21-24]. The sodium bicarbonate hydration regimen in 13 studies was described as same as Merten et al, the infusion of sodium bicarbonate was at a rate of 3 ml·kg⁻¹·h⁻¹ for 1 h before and 1 ml·kg⁻¹·h⁻¹ for 6 h after the procedure.

Primary outcome

CIN occurred in a total of 158 patients out of 2,130 patients received sodium bicarbonate compared with that of 217 patients from 2,150 patients received saline, a lower overall incidence of CIN was found in the sodium bicarbonate group (Figure 2). The pooled OR was 0.67 (95%CI: 0.47-0.96; P=0.027) also in favor of sodium

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

bicarbonate (Figure 2).

However, moderate heterogeneity ($I^2=48\%$, P=0.008) across studies was found (Figure 2).

Therefore, subgroup analyses were constructed using random effects model and showed a more pronounced effect of sodium bicarbonate in studies using low-osmolar contrast media (OR 0.59; 95%CI: 0.37-0.93, P=0.024) (Table 3). Similarly, subgroup analysis by settings suggested lower odds of CIN with sodium bicarbonate in studies with patients undergoing emergency procedures (OR 0.16; 95%CI 0.05-0.51, P=0.022) (Table 3). The effect of sodium bicarbonate was considered greater in articles reported pre-2008 (OR 0.19; 95%CI:0.09-0.41, P<0.001) (Table 3). Subgroup analysis based on the manner of sodium bicarbonate administration indicated a better effect in patients given a bolus injection (OR 0.15; 95%CI: 0.04-0.54, P=0.004) (Table 3). Sodium bicarbonate in combination with NAC demonstrated a more salient efficacy in preventing CIN (OR 0.17; 95%CI: 0.04-0.79, P=0.024) (Table 3).

Influence analysis showed no individual study had an excessive influence on the overall estimate odds ratios and 95%CI (Figure 4).

Begg' funnel plot and Egger' test (*P*=0. 396) implied no significant publication bias in this study (Figure 5).

Secondary outcomes

The requirement for dialysis

The requirement for dialysis was described in a total of 17 studies (n=3, 633). In 8 of these studies, there was no dialysis event in both groups [11,12,15,16,18,19,22,24].

BMJ Open: first published as 10.1136/bmjopen-2014-006989 on 17 March 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Overall, 14 out of 1,809 patients who treated with sodium bicarbonate compared with 13 out of 1, 824 patients treated with saline that underwent dialysis. No statistical significant difference was observed (OR 1.08; 95%CI: 0.52-2.25, P=0.841) (Figure 3a). Nonetheless, the OR for the requirement of dialysis suggested that maybe sodium bicarbonate was no better than saline in reducing the dialysis events.

Mortality

Post-procedural death was described in a total of 12 studies (n=2, 559), of these, 6 studies reported no death in either group [11,13,14,16,23,24]. There were 15 deaths in the 1, 279 patients treated with sodium bicarbonate and 22 in the 1, 280 patients treated with saline. Although there was no significant difference between the two arms (OR 0.69; 95%CI: 0.36-1.32, P=0. 263) (Figure 3b), a trend toward lower mortality risk was found in sodium bicarbonate arm compared with saline arm.

Discussion

Although CIN is generally regarded as a transient decline in renal function after contrast procedures, it cannot be regarded as a benign complication [25,26]. It accounts for 12% of all cases of acute renal failure [27]. In an observational study, 0.8% of included patients undergoing coronary angiography or interventional procedures started dialysis and 13% of them needed a permanent one [28]. Furthermore, the development of CIN is associated with a longer hospital stay, an increased morbidity and mortality, in addition to a higher financial cost. Consequently, we can never be blind to the hazard of CIN.

Various risk factors may contribute to CIN, which are divided into two groups:

BMJ Open

patient- and procedure-related [29]. Preexisting renal insufficiency and diabetes mellitus are the two main patient-related risk factors. That is one reason why we focus on the patients with a history of renal insufficiency. Renal insufficiency was usually defined as a decrease in eGFR and since the eGFR has to be reduced by 50% before a rise in serum creatinine occurs, an elevated serum creatinine level was used as the cutoff point for the definition for renal insufficiency [21]. In a retrospective review of 938 patients with stable renal insufficiency, the overall incidence of CIN was 6.1%, and the incidence was 4.4%, 10.5%, 10.0% for patients whose eGFR was 45-60, 30-45, and \leq 30 ml/min, respectively [30]. Hence special care should be taken in patients with renal insufficiency.

In order to prevent CIN, sodium bicarbonate has been proposed by various mechanisms [31,32]. Namely, how does it work remains unknown. Some potential mechanisms speculated are that alkalinizing the tubular urine with sodium bicarbonate may attenuate free radical formation and peroxide injury [28]. Oxygen free radicals and peroxide usually generate in acidic conditions, infusion of sodium bicarbonate could increase the PH of local renal tissue to neutral or slightly alkaline, thereby reducing the production of free radicals and peroxide. Merten et al. [19] first introduced the administration of sodium bicarbonate in a concentration of 154 mmol/L to prevent CIN. In our study, hydration regimens of 13 trials [9-17,19-21,33] were performed similarly to "Merten protocol". Although most previous systematic reviews and relevant meta-analyses demonstrated that sodium bicarbonate infusion could decrease the incidence of CIN [25, 26, 34-42], secondary clinical endpoints as

BMJ Open: first published as 10.1136/bmjopen-2014-006989 on 17 March 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open: first published as 10.1136/bmjopen-2014-006989 on 17 March 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

diverse as renal replacement therapy and mortality were not ameliorated. Furthermore, a retrospective cohort study of 7, 977 patients at Mayo Clinic drew a surprising conclusion: sodium bicarbonate was associated with an increased incidence of CIN [43]. By contrast with a majority of RCTs using creatinine elevations within 48-72 h after contrast exposure to define CIN, From et al. extended the definition time of CIN to a week based on the fact that creatinine may peak 3 to 7 days after contrast. However, this issue remains to be discussed. Since in our study, all patients had a history of renal insufficiency, the peak of serum creatinine may advance.

In this meta-analysis, the underlying sources of moderate heterogeneity should be taken into account, because the study subjects, study settings and type of contrast media were varied. In this case, subgroup analyses were conducted and the results revealed significant differences between emergency and elective procedures, the protective role of sodium bicarbonate played better in the former than the latter. In a meta-analysis [42] of the effect of sodium bicarbonate for the prevention of CIN, subgroup analyses also showed a more pronounced efficacy of sodium bicarbonate in 3 trials [18,33,44] included patients undergoing emergency procedures compared with those undergoing elective procedures. But the exact mechanism by which sodium bicarbonate results in a decrease incidence of CIN is still a mystery. Maybe it's related to the manner of administration and dosage. Similarly, sodium bicarbonate was more beneficial in patients who received low-osmolar contrast agents [45,46]. However, since the significantly fewer patients received iso-osmolar contrast media (n=1, 189) compared with those received low-osmolar ones (n=2,823), the major reason

responsible for the more salient effect of sodium bicarbonate was difficult to elucidate.

Although the utilization of N-acetylcysteine (NAC) has been known to reduce the incidence of CIN and whose value has been detected by many studies, the definitive effect of NAC is not yet established. A number of trials and meta-analyses indicated the combination of sodium bicarbonate and NAC is superior to either regimen in preventing of CIN. 3 studies [20,44,47] included patients who received NAC in both groups after the infusion of sodium bicarbonate or saline and the results were also in favor of sodium bicarbonate. The BINARIO study [48] indicated that hydration with sodium bicarbonate in addition to high-dose NAC in the setting of urgent PCI for STEMI was associated with a net clinical benefit. However, Yang et al. [27] and Thayssen et al. [49] concluded that use of NAC caused no significant reduction in the incidence of CIN. In our study, since only one trial [20] using NAC included in the sub-analysis, the effect of which may be overestimated (OR 0.17; 95%CI: 0.04-0.79, P=0. 024). Accordingly, more large-scale and well-designed RCTs are warranted to determine whether sodium bicarbonate plus NAC is more useful in preventing CIN than either alone.

BMJ Open: first published as 10.1136/bmjopen-2014-006989 on 17 March 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Many studies have already shown patients with CIN have greater risks for the renal replacement therapy and death. In fact, almost all the dialysis and death events occurred in patients with high-risk factors for CIN. So we could not rely on sodium bicarbonate alone to improve the bad situations caused by CIN and underlying diseases, such as renal insufficiency, diabetes mellitus. Maybe that is one reason why

we did not find significant differences in both requirement of dialysis and mortality. However, insufficient power of included RCTs could be another reason. In this meta-analysis, not all studies described renal replacement therapy and mortality and sample sizes were relatively small. So this issue remains to be explored in the future.

Conclusions

Our meta-analysis demonstrates sodium bicarbonate is superior to saline for the prevention of CIN in patients with preexisting renal insufficiency undergoing procedures using contrast media. However, use of sodium bicarbonate did not result in obvious benefit in reducing the requirement for dialysis and the mortality. Therefore, larger trials are required to detect the efficacy of sodium bicarbonate in preventing CIN and improving the clinical prognosis of patients with CIN.

Footnotes

Contributors: B.Z, L.L and WB.C searched the studies. B.Z wrote the manuscript.

L.L, WB.C, CH.L and SX.Z reviewed, analyzed and helped write the manuscript.

All authors contributed to the conception and design of this study.

Funding: This study was supported by grants from the National Scientific Foundation

of China (81171329) and the Guangdong Science Foundation (S2011010000790).

Competing interests: None.

Provenance and peer review: Not commissioned; externally peer reviewed.

Data sharing statement: No additional data are available.

60

StudyCases $\overline{\text{Bicarbonate}}$ SalineMale (%)% $\overline{\text{Bicarbon}}$ Merten11966.7*69.2*73/7650/46NA1.89*Ozcan17668.0*70.0*76/7542/4875/811.36*Masuda5975.0 \pm 8.076.0 \pm 11.063/5927/35NA1.31 \pm 0.REMEDIAL21970.0 \pm 9.071.0 \pm 9.088/8149/5592/872.04*Adolph14570.1 \pm 8.472.7 \pm 6.675/8137/2883/911.54 \pm 0.Brar32371.0*71.0*62/6543/46NA1.49*Maioli50274.0*74.0*57/6125/2359/571.21 \pm 0.Tamura14472.3 \pm 9.973.3 \pm 7.792/8360/5785/831.36 \pm 0.Vasheghani26562.9 \pm 10.063.8 \pm 9.084/8222/2130/411.63 \pm 0.Vasheghani26562.9 \pm 10.063.8 \pm 9.084/8222/2130/411.63 \pm 0.Vasheghani(2)7261.4#62.7#78/8133/3866/711.77 \pm Motohiro15571.0 \pm 9.074.0 \pm 7.076/6456/6386/831.54 \pm 0.PREVENT38265.8*67.5*71/71100/10077/801.50 \pm 0.Ueda5977.0 \pm 9.075.0 \pm 10.077/7910/10NA1.32 \pm 0.Klima17678.0*75.0*66/6239/3490/81<
Ozcan 176 68.0* 70.0* 76/75 42/48 75/81 1.36* Masuda 59 75.0±8.0 76.0±11.0 63/59 27/35 NA 1.31±0. REMEDIAL 219 70.0±9.0 71.0±9.0 88/81 49/55 92/87 2.04* Adolph 145 70.1±8.4 72.7±6.6 75/81 37/28 83/91 1.54±0. Brar 323 71.0* 71.0* 62/65 43/46 NA 1.49* Maioli 502 74.0* 74.0* 57/61 25/23 59/57 1.21±0. Tamura 144 72.3±9.9 73.3±7.7 92/83 60/57 85/83 1.36±0. Vasheghani 265 62.9±10.0 63.8±9.0 84/82 22/21 30/41 1.63±0. Vasheghani(2) 72 61.4# 62.7# 78/81 33/38 66/71 1.77# Motohiro 155 71.0±9.0 74.0±7.0 76/64 56/63 86/83
Masuda 59 75.0±8.0 76.0±11.0 63/59 27/35 NA 1.31±0. REMEDIAL 219 70.0±9.0 71.0±9.0 88/81 49/55 92/87 2.04* Adolph 145 70.1±8.4 72.7±6.6 75/81 37/28 83/91 1.54±0. Brar 323 71.0* 71.0* 62/65 43/46 NA 1.49# Maioli 502 74.0* 74.0* 57/61 25/23 59/57 1.21±0. Tamura 144 72.3±9.9 73.3±7.7 92/83 60/57 85/83 1.36±0. Vasheghani 265 62.9±10.0 63.8±9.0 84/82 22/21 30/41 1.63±0. Vasheghani(2) 72 61.4# 62.7# 78/81 33/38 66/71 1.77# Motohiro 155 71.0±9.0 74.0±7.0 76/64 56/63 86/83 1.54±0. PREVENT 382 65.8* 67.5* 71/71 100/100 77/80 1.50* Ueda 59 77.0±9.0 75.0±10.0 77/79
REMEDIAL 219 70.0±9.0 71.0±9.0 88/81 49/55 92/87 2.04* Adolph 145 70.1±8.4 72.7±6.6 75/81 37/28 83/91 1.54±0. Brar 323 71.0* 71.0* 62/65 43/46 NA 1.49# Maioli 502 74.0* 74.0* 57/61 25/23 59/57 1.21±0. Tamura 144 72.3±9.9 73.3±7.7 92/83 60/57 85/83 1.36±0. Vasheghani 265 62.9±10.0 63.8±9.0 84/82 22/21 30/41 1.63±0. Vasheghani(2) 72 61.4# 62.7# 78/81 33/38 66/71 1.77# Motohiro 155 71.0±9.0 74.0±7.0 76/64 56/63 86/83 1.54±0. PREVENT 382 65.8* 67.5* 71/71 100/100 77.80 1.50±0. Klima 176 78.0* 75.0* 66/62 39/34 90/81 1.60* Gomes 301 64.1±12.0 64.5±12.0 15/75
Adolph 145 70.1±8.4 72.7±6.6 75/81 37/28 83/91 1.54±0. Brar 323 71.0* 71.0* 62/65 43/46 NA 1.49# Maioli 502 74.0* 74.0* 57/61 25/23 59/57 1.21±0. Tamura 144 72.3±9.9 73.3±7.7 92/83 60/57 85/83 1.36±0. Vasheghani 265 62.9±10.0 63.8±9.0 84/82 22/21 30/41 1.63±0. Castini 103 70.0±8.3 72.7±8.2 85/84 35/20 71/78 1.59±0. Vasheghani(2) 72 61.4# 62.7# 78/81 33/38 66/71 1.77# Motohiro 155 71.0±9.0 74.0±7.0 76/64 56/63 86/83 1.54±0. PREVENT 382 65.8* 67.5* 71/71 100/100 77/80 1.50*0. Klima 176 78.0* 75.0* 66/62 39/34 90/81 1.60* Gomes 301 64.1±12.0 64.5±12.0 15/75
Brar 323 71.0* 71.0* 62/65 43/46 NA 1.49# Maioli 502 74.0* 74.0* 57/61 25/23 59/57 1.21±0. Tamura 144 72.3±9.9 73.3±7.7 92/83 60/57 85/83 1.36±0. Vasheghani 265 62.9±10.0 63.8±9.0 84/82 22/21 30/41 1.63±0. Castini 103 70.0±8.3 72.7±8.2 85/84 35/20 71/78 1.59±0. Vasheghani(2) 72 61.4# 62.7# 78/81 33/38 66/71 1.77# Motohiro 155 71.0±9.0 74.0±7.0 76/64 56/63 86/83 1.54±0. PREVENT 382 65.8* 67.5* 71/71 100/100 77/80 1.50*0. Ueda 59 77.0±9.0 75.0±10.0 77/79 10/10 NA 1.32±0. Klima 176 78.0* 75.0* 66/62 39/34 90/81
Maioli 502 74.0* 74.0* 57/61 25/23 59/57 1.21±0. Tamura 144 72.3±9.9 73.3±7.7 92/83 60/57 85/83 1.36±0. Vasheghani 265 62.9±10.0 63.8±9.0 84/82 22/21 30/41 1.63±0. Castini 103 70.0±8.3 72.7±8.2 85/84 35/20 71/78 1.59±0. Vasheghani(2) 72 61.4# 62.7# 78/81 33/38 66/71 1.77# Motohiro 155 71.0±9.0 74.0±7.0 76/64 56/63 86/83 1.54±0. PREVENT 382 65.8* 67.5* 71/71 100/100 77/80 1.50*0. Ueda 59 77.0±9.0 75.0±10.0 77/79 10/10 NA 1.32±0. Klima 176 78.0* 75.0* 66/62 39/34 90/81 1.60*0. Gomes 301 64.1±12.0 64.5±12.0 15/75 29/30 77/74 1.50±0. Hafiz 320 74.0* 73.0* 57/57 </td
Tamura 144 72.3±9.9 73.3±7.7 92/83 60/57 85/83 1.36±0. Vasheghani 265 62.9±10.0 63.8±9.0 84/82 22/21 30/41 1.63±0. Castini 103 70.0±8.3 72.7±8.2 85/84 35/20 71/78 1.59±0. Vasheghani(2) 72 61.4# 62.7# 78/81 33/38 66/71 1.77# Motohiro 155 71.0±9.0 74.0±7.0 76/64 56/63 86/83 1.54±0. PREVENT 382 65.8* 67.5* 71/71 100/100 77/80 1.50*0. Ueda 59 77.0±9.0 75.0±10.0 77/79 10/10 NA 1.32±0. Klima 176 78.0* 75.0* 66/62 39/34 90/81 1.60*0. Gomes 301 64.1±12.0 64.5±12.0 15/75 29/30 77/74 1.50±0. Hafiz 320 74.0* 73.0* 57/57 49/45 95/94 1.65*
Vasheghani 265 62.9±10.0 63.8±9.0 84/82 22/21 30/41 1.63±0. Castini 103 70.0±8.3 72.7±8.2 85/84 35/20 71/78 1.59±0. Vasheghani(2) 72 61.4# 62.7# 78/81 33/38 66/71 1.77# Motohiro 155 71.0±9.0 74.0±7.0 76/64 56/63 86/83 1.54±0. PREVENT 382 65.8* 67.5* 71/71 100/100 77/80 1.50* Ueda 59 77.0±9.0 75.0±10.0 77/79 10/10 NA 1.32±0. Klima 176 78.0* 75.0* 66/62 39/34 90/81 1.60* Gomes 301 64.1±12.0 64.5±12.0 15/75 29/30 77/74 1.50±0. Hafiz 320 74.0* 73.0* 57/57 49/45 95/94 1.65*
Castini103 70.0 ± 8.3 72.7 ± 8.2 $85/84$ $35/20$ $71/78$ 1.59 ± 0.5 Vasheghani(2)72 $61.4\#$ $62.7\#$ $78/81$ $33/38$ $66/71$ $1.77\#$ Motohiro155 71.0 ± 9.0 74.0 ± 7.0 $76/64$ $56/63$ $86/83$ $1.54\pm 0.54\%$ PREVENT 382 $65.8*$ $67.5*$ $71/71$ $100/100$ $77/80$ 1.50% Ueda59 77.0 ± 9.0 75.0 ± 10.0 $77/79$ $10/10$ NA $1.32\pm 0.50\%$ Klima 176 $78.0*$ $75.0*$ $66/62$ $39/34$ $90/81$ 1.60% Gomes301 64.1 ± 12.0 64.5 ± 12.0 $15/75$ $29/30$ $77/74$ $1.50\pm 0.5\%$ Hafiz 320 $74.0*$ $73.0*$ $57/57$ $49/45$ $95/94$ 1.65%
Vasheghani(2) 72 61.4# 62.7# 78/81 33/38 66/71 1.77# Motohiro 155 71.0±9.0 74.0±7.0 76/64 56/63 86/83 1.54±0. PREVENT 382 65.8* 67.5* 71/71 100/100 77/80 1.50* Ueda 59 77.0±9.0 75.0±10.0 77/79 10/10 NA 1.32±0. Klima 176 78.0* 75.0* 66/62 39/34 90/81 1.60* Gomes 301 64.1±12.0 64.5±12.0 15/75 29/30 77/74 1.50±0. Hafiz 320 74.0* 73.0* 57/57 49/45 95/94 1.65*
Motohiro 155 71.0±9.0 74.0±7.0 76/64 56/63 86/83 1.54±0. PREVENT 382 65.8* 67.5* 71/71 100/100 77/80 1.50* Ueda 59 77.0±9.0 75.0±10.0 77/79 10/10 NA 1.32±0. Klima 176 78.0* 75.0* 66/62 39/34 90/81 1.60* Gomes 301 64.1±12.0 64.5±12.0 15/75 29/30 77/74 1.50±0. Hafiz 320 74.0* 73.0* 57/57 49/45 95/94 1.65*
PREVENT 382 65.8* 67.5* 71/71 100/100 77/80 1.50* Ueda 59 77.0±9.0 75.0±10.0 77/79 10/10 NA 1.32±0. Klima 176 78.0* 75.0* 66/62 39/34 90/81 1.60* Gomes 301 64.1±12.0 64.5±12.0 15/75 29/30 77/74 1.50±0. Hafiz 320 74.0* 73.0* 57/57 49/45 95/94 1.65*
Ueda 59 77.0±9.0 75.0±10.0 77/79 10/10 NA 1.32±0. Klima 176 78.0* 75.0* 66/62 39/34 90/81 1.60* Gomes 301 64.1±12.0 64.5±12.0 15/75 29/30 77/74 1.50±0. Hafiz 320 74.0* 73.0* 57/57 49/45 95/94 1.65*
Klima17678.0*75.0*66/6239/3490/811.60*Gomes30164.1±12.064.5±12.015/7529/3077/741.50±0.Hafiz32074.0*73.0*57/5749/4595/941.65*
Gomes 301 64.1±12.0 64.5±12.0 15/75 29/30 77/74 1.50±0. Hafiz 320 74.0* 73.0* 57/57 49/45 95/94 1.65*
Hafiz 320 74.0* 73.0* 57/57 49/45 95/94 1.65*
Kristeller 92 72.0±11.0 73.0±11.0 64/52 52/38 89/92 NA
Boucek 120 63.0# 67.0# 75/75 NA NA 1.92#
Kooiman 548 71.6# 72.5# 60/61 27/27 NA NA
Note: DM=diabetes mellitus HT=hypertension eGFR=estimated glomerular filtrat
*median value #mean value

eGFR(ml/min/1.73m²)

Saline

45.0*

NA 38.7±15.4

71.0±9.0

NA

48.3#

NA

 38.2 ± 0.2

45.4±12.0

49.9±10.3

44.2#

42.8±13.8

46.0*

38.7±12.6

43.0#

51.9±13

40.5*

49.4#

44.6#

50.9#

Bicarbonate

41.0*

NA

40.2±15.4

32.0±7.0

NA

47.7#

NA

40.0±7.5

46.4±12.0

46.9±12.8

42.7#

45.7±12.9

46.0*

42.4±11.5

43.1#

50.5±13.0

41.5*

48.9#

43.6#

49.9#

NA= not applicable

1.32±0.65

1.57±0.36

 1.20 ± 0.30

1.38±0.19

 1.66 ± 0.50

 1.49 ± 0.30

1.55±0.44

1.51±0.59

 1.49 ± 0.50

1.60*

BMJ Open: first published as 10.1136/bmjopen-2014-006989 on 17 March 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Draadura	Intomastica-	Contrast type and Volume(ml)	Undration regimen	Definition of CDI	
Procedure	Interventions	Bicarbonate Saline	- Hydration regimen	Definition of CIN	
Elective diagnostic /interventional procedures	SB vs. SC	NA NA Iopamidol,nonionic,Low-osmolar	3ml·kg ⁻¹ ·h ⁻¹ for 1h before and 1ml·kg ⁻¹ ·h ⁻ for 6h after the procedure of SB or SC	Scr↑≥25% within 2d	
Elective CAG/PCI	SB vs. SC	100* 100* Ioxaglate,ionic,Low-osmolar	1ml·kg ⁻¹ ·h ⁻¹ for 6h before and after the procedure of SB or SC	Scr↑>0.5mg/dl or 25% within 2d	
Emergency CAG/PCI	SB vs. SC	112±89 120±61 Iopamidol,nonionic,Low-osmolar	$3ml \cdot kg^{-1} \cdot h^{-1}$ for 1h before and $1ml \cdot kg^{-1} \cdot h^{-1}$ for 6h after the procedure of SB or SC	Scr↑>0.5mg/dl or 25% within 2d	
Elective CAG/ PCI /peripheral procedure	SB+NAC vs. NS+NAC	169±92 179±9 Iodixanol,nonionic,Iso- osmolar	$3ml \cdot kg^{-1} \cdot h^{-1}$ for 1h before and $1ml \cdot kg^{-1} \cdot h^{-1}$ for 6h after:SB; $1ml \cdot kg^{-1} \cdot h^{-1}$ for 12h before and 12h after:NS	Scr↑≥25% within 2c	
Elective CAG/PCI	SB vs. SC	141±50 138±52 Iodixanol,nonionic,Iso- osmolar	$2ml \cdot kg^{-1} \cdot h^{-1}$ for 2h before and $1ml \cdot kg^{-1} \cdot h^{-1}$ for 6h after the procedure of SB or SC	Scr↑>0.5mg/dl or 25% within 2d	
Elective CAG	SB vs. SC	126* 137* Ioxilan,nonionic,Iso- osmolar	$3ml \cdot kg^{-1} \cdot h^{-1}$ for 1h before and $1.5ml \cdot kg^{-1} \cdot h^{-1}$ for 4h after the procedure of SB or SC	eGFR↓>25% within 4d	
Elective CAG/PCI	SB vs. IS	160* 170* Iodixanol,nonionic,Iso- osmolar	$3ml\cdot kg^{-1}\cdot h^{-1}$ for 1h before and $1ml\cdot kg^{-1}\cdot h^{-1}$ for 6h after:SB; $1ml\cdot kg^{-1}\cdot h^{-1}$ for 12h after:IS	Scr↑≥0.5mg/dl within 5d	
Elective CAG/PCI	Bolus SB+SC vs. SC	82±40 88±45 Iohexol,nonionic,Low-osmolar	Single-bolus SB 20ml for 5min before and SC 1ml·kg ⁻¹ ·h ⁻¹ for 12h pre- and post- procedure; 1ml·kg ⁻¹ ·h ⁻¹ for 12h pre- and post-procedure of SC	Scr↑>0.5mg/dl or 25% within 3d	
Elective CAG	SB+Is vs. IS	115±41 113.2±36 Iohexl,nonionic,Low-osmolar	$3ml \cdot kg^{-1} \cdot h^{-1}$ for 1h before and $1ml \cdot kg^{-1} \cdot h^{-1}$ for 6h after in both groups	Scr↑≥0.5mg/dl or 25% within 2d	
Elective CAG/PCI	SB vs. SC	179±125 196±128 Iodixanol,nonionic,Low-osmolar	$3ml \cdot kg^{-1} \cdot h^{-1}$ for 1h before and $1ml \cdot kg^{-1} \cdot h^{-1}$ for 6h after:SB; $1ml \cdot kg^{-1} \cdot h^{-1}$ for 12h before and after:SC	Scr↑≥25% within 5c	
Note: CAG=coron IS=isotonic s		PCI=percutaneous coronary inter ?=N-acetylcysteine NS=normal sa		odium chloride	

Table	1.	Continued

Procedure	Interventions -		and Volume(ml)	- Hydration regimen	Definition of CIN	
		Bicarbonate	Saline			
Elective CAG	SB+half SC vs. half SC		123# I,nonionic, •osmolar	3ml·kg ⁻¹ ·h ⁻¹ for 1h before and 1ml·kg ⁻¹ ·h ⁻¹ for 6h after the procedure of 75ml SB to1L of 0.45%SC; 1075ml 0.45%SC	Scr↑≥0.5mg/dl or 25% within 2d	
Elective CAG/PCI	SB+SC vs. SC	-	130±40 ol, nonionic, osmolar	 1ml·kg⁻¹·h⁻¹ SC 12h before and 1ml·kg⁻¹·h⁻¹ SB from 3h pre-to 6h post-procedure, then 1ml·kg⁻¹·h⁻¹ SC for 12h; 1ml·kg⁻¹·h⁻¹ SC 12h pre- and 12h post- procedure 	Scr↑≥0.5mg/dl or>25% within 2d	
Elective CAG/ angioplasty/ endovascular intervention	SB vs SC		120* ol,nonionic , osmolar	3ml·kg ⁻¹ ·h ⁻¹ for 1h before and 1ml·kg ⁻¹ ·h ⁻¹ for 6h after:SB; 1ml·kg ⁻¹ ·h ⁻¹ for 12h:SC		
Emergency CAG/ PCI	SB vs SC	_	104±57 lol/Iohexol, osmolar	Bolus 0.5mg/ml SB before and SC 1ml·kg ⁻¹ ·h ⁻¹ for 6h during and after in both groups	Scr ≥ 0.5 mg/dl or >25% within 2d	
Elective CAG/ PCI/ PTA/CT/ PAG	SB vs SC	-	100* e/iohexol.etc. w-osmolar	$3ml \cdot kg^{-1} \cdot h^{-1}$ for 1h before and $1ml \cdot kg^{-1} \cdot h^{-1}$ for 6h after:SB; $1ml \cdot kg^{-1} \cdot h^{-1}$ for 24h:SC	Scr↑≥0.5mg/dl or 25% within 2d	
Elective CAG/PCI	SB vs NS		5 125±87 x/Loxaglate, •osmolar	$3ml \cdot kg^{-1} \cdot h^{-1}$ for 1h before and $1ml \cdot kg^{-1} \cdot h^{-1}$ for 6h after the procedure of SB or NS	Scr↑≥0.5mg/dl within 2d	
Elective CAG/ PAG/ intervention	SB±NAC vs NS±NAC	-	100* amidol/Ioversol, Low-osmolar	3ml·kg ⁻¹ ·h ⁻¹ for 1h before and 1ml·kg ⁻¹ ·h ⁻¹ for 6h after:SB; 1ml·kg ⁻¹ ·h ⁻¹ for 12h before and 12h after:NS	Scr↑>0.5mg/dl or 25% within 2d	
Elective CPB	SB vs IS	74#	83# NA	3ml·kg ⁻¹ ·h ⁻¹ for 1h before and 1ml·kg ⁻¹ ·h ⁻¹ for 6h after the procedure of SB or IS	Scr $\uparrow \ge 0.3$ mg/dl or 50% or Urine output <0.5 ml·kg ⁻¹ ·h ⁻¹ (>6h) within 5d	
Elective CAG/ Lower-limb angiography and /or angioplasty	SB vs NS		104# d,nonionic , osmolar	3ml·kg ⁻¹ ·h ⁻¹ for 1h before and 1ml·kg ⁻¹ ·h ⁻¹ for 6h after the procedure of SB or SC	Scr↑≥0.5mg/dl or 25% within 2d	
Elective CECT	SB vs IS	1	104.7# l/Iobitridol/ Low-osmolar	250ml SB for 1h before; 1000ml IS before and 1000ml IS after	Scr↑>0.5mg/dl or 25% within 4d	

Table 2. Quality assessment of included studies

Included trials	Trial described as randomized (1=yes, 0=no)	Randomized method described & appropriate (1=yes, 0=no)	Allocation concealment described† (1=yes, 0=no)	Allocation concealment described & appropriate	Trial described as double blind (1=yes, 0=no)	Double blind method described & appropriate	Withdrawals & Dropouts described (1=yes,0=no)	Jadad score
				(1=yes, 0=no)		(1=yes,0=no)	` -	
Merten	1	1	0	0	0	0	1	4
Ozcan	1	0	0	0	0	0	1	2
Masuda	1		0	0	0	0	1	4
REMEDIAL	1	1	0	0	1	0	1	5
Adolph	1	1	0	0	1	0	1	5
Brar	1	1	1	1	0	0	1	5
Maioli	1	1	1	1	0	0	0	4
Tamura	1	1	0	0	0	0	1	4
Vasheghani	1	1	0	0	1	0	0	4
Castini	1	1	0	0	0	0	0	3
Vasheghani(2)	1	1	0	0	1	0	0	4
Motohiro	1	1	0	0	0	0	1	4
PREVENT	1	1	0	0	0	0	1	4
Ueda	1	1	0	0	0	0	0	3
Klima	1	0	1	1	0	0	0	3
Gomes	1	0	1	1	0	0	0	3
Hafiz	1	1	0	0	0	0	1	4
Kristeller	1	1	1	1	1	0	0	5
Boucek	1	1	1	1	1	0	1	6
Kooiman	1	1	0	0	0	0	1	4

Note: †One point can be obtained from Jadad Score if randomization method of the trial is described & appropriate

*Calculation for quality assessment of included trials: low, 1-3; high, 4-7

Table 3. Subgroup analyses used to assess the effect of sodium bicarbonate in various
conditions

Trials/patients	OR(95%CI)	Test for overall effect	Heterogeneity
14/2823	0.59[0.37,0.93]	Z=2.26(P=0.024)	χ ² =26.61,df=13(<i>P</i> =0.014), I ² =51%
4/1189	0.76[0.43,1.34]	Z=0.93(P=0.351)	χ ² =4.67, df=3(<i>P</i> =0.198), I ² =36%
18/4162	0.76[0.54,1.06]	Z=1.62(P=0.105)	χ ² =29.54,df=17(<i>P</i> =0.030), I ² =43%
2/118	0.16[0.05,0.51]	Z=3.11(P=0.002)	χ ² =0.07,df=1(<i>P</i> =0.784), I ² =0%
1/219	0.17[0.04,0.79]	Z=2.26(P=0.024)	Not applicable
18/3741	0.71[0.48,1.03]	Z=1.80(P=0.071)	χ ² =33.13, df=17(<i>P</i> =0.011), I ² =49%
4/573	0.19[0.09,0.41]	Z=4.26(P=0.000)	χ ² =1.06, df=10(<i>P</i> =0.788), I ² =0%
16/3707	0.85[0.62,1.16]	Z=1.03(P=0.302)	χ ² =22.13, df=15(<i>P</i> =0.105), I ² =32%
ration			
18/4077	0.75[0.53,1.05]	Z=1.69(P=0.091)	χ ² =30.21, df=17(<i>P</i> =0.025), I ² =44%
2/203	0.15[0.04,0.54]	Z=2.90(P=0.004)	χ ² =0.23, df=1(<i>P</i> =0.632), I ² =0%
	14/2823 4/1189 18/4162 2/118 1/219 18/3741 4/573 16/3707 ration 18/4077	14/2823 0.59[0.37,0.93] 4/1189 0.76[0.43,1.34] 18/4162 0.76[0.54,1.06] 2/118 0.16[0.05,0.51] 1/219 0.17[0.04,0.79] 18/3741 0.71[0.48,1.03] 4/573 0.19[0.09,0.41] 16/3707 0.85[0.62,1.16] ration 18/4077	14/2823 $0.59[0.37, 0.93]$ $Z=2.26(P=0.024)$ $4/1189$ $0.76[0.43, 1.34]$ $Z=0.93(P=0.351)$ $18/4162$ $0.76[0.54, 1.06]$ $Z=1.62(P=0.105)$ $2/118$ $0.16[0.05, 0.51]$ $Z=3.11(P=0.002)$ $1/219$ $0.17[0.04, 0.79]$ $Z=2.26(P=0.024)$ $1/219$ $0.17[0.04, 0.79]$ $Z=2.26(P=0.024)$ $1/8/3741$ $0.71[0.48, 1.03]$ $Z=1.80(P=0.071)$ $4/573$ $0.19[0.09, 0.41]$ $Z=4.26(P=0.000)$ $16/3707$ $0.85[0.62, 1.16]$ $Z=1.03(P=0.302)$ ration $18/4077$ $0.75[0.53, 1.05]$ $Z=1.69(P=0.091)$ $2/203$ $0.15[0.04, 0.54]$ $Z=2.90(P=0.004)$

Figure legends

Figure 1. Flow diagram of included studies

Figure 2. The forest plot of odds ratios of contrast-induced nephropathy

Figure 3a. The forest plot of odds ratios of the requirement for dialysis

Figure 3b. The forest plot of odds ratios of the mortality

Figure 4. The influence of an individual study on the overall estimates

Figure 5. Funnel plot with pseudo 95% confidence limits

References

1 Golshahi J, Nasri H, Gharipour M, et al. Contrast-induced nephropathy; A literature review[J]. J Nephropathol 2014; 3(2): 51-6

2 Humbert A, Kissling S, Teta D. Contrast-induced nephropathy[J].Rev Med Suisse

2013; 9(389): 1222-1228.

3 Mohammed NMA, Mahfouz A, Achkar K, et al. Contrast-induced nephropathy[J]. Heart views 2013; 14(3): 106-16.

4 Silva RG, Silva NG, Lucchesi F, et al. Prevention of contrast-induced nephropathy by use of bicarbonate solution: preliminary results and literature review[J].Jornal Brasileiro de Nefrologia 2010; 32(3): 292-302.

5 Weisbord SD, Chen H, Stone RA, et al. Associations of increases in serum creatinine with mortality and length of hospital stay after coronary angiography[J]. JASN 2006; 17(10): 2871-2877.

6 Subedi B, Siddique MA, Zaman SM, et al. Contrast induced nephropathy in patients

BMJ Open

with pre-existing renal impairment undergoing coronary angiogram and percutaneous transluminal coronary angioplasty[J].Mymensingh medical journal 2011; 20(2): 270-274.

7 Adolph E, Holdt-Lehmann B, Chatterjee T, et al. Renal Insufficiency Following Radiocontrast Exposure Trial (REINFORCE): a randomized comparison of sodium bicarbonate versus sodium chloride hydration for the prevention of contrast-induced nephropathy[J]. Coron Artery Dis 2008; 19(6): 413-419.

8 Brar SS, Shen AY, Jorgensen M, et al. Sodium bicarbonate vs sodium chloride for the prevention of contrast medium–induced nephropathy in patients undergoing coronary angiography: a randomized trial[J]. Jama 2008; 300(9): 1038-1046.
9 Maioli M, Toso A, Leoncini M, et al. Sodium bicarbonate versus saline for the prevention of contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention[J]. J Am Coll Cardio 2008; 52(8): 599-604.

BMJ Open: first published as 10.1136/bmjopen-2014-006989 on 17 March 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES)

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

10 Vasheghani-Farahani A, Sadigh G, Kassaian SE, et al. Sodium bicarbonate plus isotonic saline versus saline for prevention of contrast-induced nephropathy in patients undergoing coronary angiography: a randomized controlled trial[J]. Am J Kidney Dis 2009; 54(4): 610-618.

11 Vasheghani-Farahani A, Sadigh G, Ebrahim Kassaian S, et al. Sodium bicarbonate in preventing contrast nephropathy in patients at risk for volume overload: a randomized controlled trial[J]. J Nephrol 2010; 23(2): 216. 12 Castini D, Lucreziotti S, Bosotti L, et al. Prevention of Contrast - induced Nephropathy: A Single Center Randomized Study[J]. Clin Cardiol 2010; 33(3): E63-E68.

13 Lee S W, Kim W J, Kim Y H, et al. Preventive strategies of renal insufficiency in patients with diabetes undergoing intervention or arteriography (the PREVENT Trial)[J]. Am J Cardiol 2011; 107(10): 1447-1452.

14 Hafiz AM, Jan MF, Mori N, et al. Prevention of contrast - induced acute kidney injury in patients with stable chronic renal disease undergoing elective percutaneous coronary and peripheral interventions: Randomized comparison of two preventive strategies[J]. Catheter Cardiovasc Interv 2012; 79(6): 929-937.

15 Gomes VO, Lasevitch R, Lima VC, et al. Hydration with sodium bicarbonate does not prevent contrast nephropathy: a multicenter clinical trial[J]. Arq Bras Cardiol 2012; 99(6): 1129-1134.

16 Boucek P, Havrdova T, Oliyarnyk O, et al. Prevention of contrast-induced nephropathy in diabetic patients with impaired renal function: A randomized, double blind trial of sodium bicarbonate versus sodium chloride-based hydration[J]. Diabetes Res Clin Pract 2013; 101(3): 303-308.

17 Kristeller JL, Zavorsky GS, Prior JE, et al. Lack of effectiveness of sodium bicarbonate in preventing kidney injury in patients undergoing cardiac surgery: a randomized controlled trial[J]. Pharmacotherapy 2013; 33(7): 710-717.

18 Ueda H, Yamada T, Masuda M, et al. Prevention of contrast-induced nephropathy
by bolus injection of sodium bicarbonate in patients with chronic kidney disease
undergoing emergent coronary procedures[J]. Am J Cardiol 2011; 107(8): 1163-1167.
19 Merten GJ, Burgess WP, Rittase RA, et al. Prevention of contrast-induced
nephropathy with sodium bicarbonate: an evidence-based protocol[J]. Crit Pathw
Cardiol 2004; 3(3): 138-143.

20 Briguori C, Airoldi F, D'Andrea D, et al. Renal Insufficiency following contrast media administration trial (REMEDIAL) A randomized comparison of 3 preventive strategies[J]. Circulation 2007; 115(10): 1211-1217.

21 Klima T, Christ A, Marana I, et al. Sodium chloride vs. sodium bicarbonate for the prevention of contrast medium-induced nephropathy: a randomized controlled trial[J]. Eur Heart J 2012; 33(16): 2071-2079.

BMJ Open: first published as 10.1136/bmjopen-2014-006989 on 17 March 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES)

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

22 Kooiman J, Sijpkens YW, de Vries JP, et al. A randomized comparison of 1-h sodium bicarbonate hydration versus standard peri-procedural saline hydration in patients with chronic kidney disease undergoing intravenous contrast-enhanced computerized tomography[J]. Nephrol Dial Transplant 2014; 29(5): 1029-36.

23 Tamura A, Goto Y, Miyamoto K, et al. Efficacy of single-bolus administration of sodium bicarbonate to prevent contrast-induced nephropathy in patients with mild renal insufficiency undergoing an elective coronary procedure[J]. Am J Cardiol 2009; 104(7): 921-925.

24 Motohiro M, Kamihata H, Tsujimoto S, et al. A new protocol using sodium bicarbonate for the prevention of contrast-induced nephropathy in patients undergoing coronary angiography[J]. Am J Cardiol 2011; 107(11): 1604-1608.

25 Meier P, Ko DT, Tamura A, et al. Sodium bicarbonate-based hydration prevents contrast-induced nephropathy: a meta-analysis[J]. BMC Med 2009; 7(1): 23.

26 Trivedi H, Nadella R, Szabo A. Hydration with sodium bicarbonate for the prevention of contrast-induced nephropathy: a meta-analysis of randomized controlled trials[J].Clin Nephrol 2010; 74(4): 288-296.

27 Yang K,Liu W, Ren W, et al. Different interventions in preventing contrast-induced nephropathy after percutaneous coronary intervention[J]. Int Urol Nephrol 2014; 46 (9): 1801-7.

28 Atkins JL. Effect of sodium bicarbonate preloading on ischemic renal failure.

Nephron 1986; 44(1): 70-74.

29 Andreucci, Michele, Richard Solomon, et al. Side Effects of Radiographic Contrast Media: Pathogenesis, Risk Factors, and Prevention[J].Biomed Res Int 2014; 2014: 741018

30 Murakami R, Hayashi H, Sugizaki K, et al. Contrast-induced nephropathy in patients with renal insufficiency undergoing contrast-enhanced MDCT[J]. Eur Radiol 2012; 22(10): 2147-2152.

31 McCullough PA, Adam A, Becker CR, et al. Risk prediction of contrast-induced nephropathy[J]. Am J Cardiol 2006; 98(6): 27-36.

32 Burgess WP, Walker PJ. Mechanisms of Contrast-Induced Nephropathy Reduction

for Saline (NaCl) and Sodium Bicarbonate (NaHCO3)[J]. Biomed Res Int 2014; 2014: 510385

33 Masuda M, Yamada T, Mine T, et al. Comparison of usefulness of sodium bicarbonate versus sodium chloride to prevent contrast-induced nephropathy in patients undergoing an emergent coronary procedure[J]. Am J Cardiol 2007; 100(5): 781-786.

34 Hogan SE, L'Allier P, Chetcuti S, et al. Current role of sodium bicarbonate–based preprocedural hydration for the prevention of contrast-induced acute kidney injury: A meta-analysis[J]. Am Heart J 2008; 156(3): 414-421.

35 Joannidis M,Schmid M, Wiedermann CJ. Prevention of contrast media-induced nephropathy by isotonic sodium bicarbonate: a meta-analysis[J].Wien Klin

Wochenschr 2008; 120(23-24): 742-8

36 Ho KM, Morgan DJ. Use of isotonic sodium bicarbonate to prevent radiocontrast nephropathy in patients with mild pre-existing renal impairment: a meta-analysis

BMJ Open: first published as 10.1136/bmjopen-2014-006989 on 17 March 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES)

and data mining, Al training, and similar technologies

Protected by copyright, including for uses related to text

[J].Anaesth Intensive Care 2008; 36(5): 646-653.

37 Navaneethan SD, Singh S, Appasamy S, et al. Sodium bicarbonate therapy for prevention of contrast-induced nephropathy: a systematic review and meta-analysis

[J]. Am J Kidney Dis 2009; 53(4): 617-627.

38 Brar SS, Hiremath S, Dangas G, et al. Sodium bicarbonate for the prevention of contrast induced-acute kidney injury: a systematic review and meta-analysis[J]. Clinical Journal of the American Society of Nephrology 2009; 4(10): 1584-1592.

39 Kanbay M, Covic A, Coca SG, et al. Sodium bicarbonate for the prevention of

contrast-induced nephropathy: a meta-analysis of 17 randomized trials[J]. Int Urol Nephrol 2009; 41(3): 617-627.

40 Hoste EA, De Waele JJ, Gevaert SA, et al. Sodium bicarbonate for prevention of contrast-induced acute kidney injury: a systematic review and meta-analysis[J]. Nephrology Dialysis Transplantation 2010; 25(3): 747-758.

41 Kunadian V, Zaman A, Spyridopoulos I, et al. Sodium bicarbonate for the prevention of contrast induced nephropathy: a meta-analysis of published clinical trials[J]. Eur J Radiol 2011; 79(1): 48-55.

42 Jang JS, Jin HY, Seo JS, et al. Sodium bicarbonate therapy for the prevention of contrast-induced acute kidney injury–a systematic review and meta-analysis[J]. Circ J 2011; 76(9): 2255-2265.

43 From AM, Bartholmai BJ, Williams AW, et al. Sodium bicarbonate is associated with an increased incidence of contrast nephropathy: a retrospective cohort study of 7977 patients at Mayo Clinic[J]. Clinical Journal of the American Society of Nephrology 2008; 3(1): 10-18.

44 Recio-Mayoral A, Chaparro M, Prado B, et al. The reno-protective effect of hydration with sodium bicarbonate plus N-acetylcysteine in patients undergoing emergency percutaneous coronary intervention: the RENO Study[J]. J Am Coll Cardiol 2007; 49(12): 1283-1288.

45 Jo SH, Youn TJ, Koo BK, et al. Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled


46 McCullough PA, Bertrand ME, Brinker JA, et al. A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media[J]. J Am Coll Cardiol 2006; 48(4): 692-699.


47 Mahmoodi K, Sohrabi B, Ilkhchooyi F, et al. The efficacy of hydration with normal saline versus hydration with sodium bicarbonate in the prevention of contrast-induced nephropathy[J]. Heart views 2014; 15(2): 33.

48 Leone AM, De Caterina AR, Sciahbasi A, et al. Sodium bicarbonate plus N-acetylcysteine to prevent contrast-induced nephropathy in primary and rescue percutaneous coronary interventions: the BINARIO (BIcarbonato e N-Acetil-cisteina nell'infaRto mIocardico acutO) study[J].EuroIntervention, 2012; 8(7): 839-847.

49 Thayssen P, Lassen JF, Jensen SE, et al. Prevention of Contrast-Induced Nephropathy With N-Acetylcysteine or Sodium Bicarbonate in Patients With ST-Segment–Myocardial Infarction A Prospective, Randomized, Open-Labeled Trial[J]. Circ Cardiovasc Interv 2014; 7(2): 216-224. BMJ Open: first published as 10.1136/bmjopen-2014-006989 on 17 March 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES)

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies





119x119mm (300 x 300 DPI)



Events. %

24/165 8.57

7/130

9/150

0.67 (0.47, 0.96) 158/2130 217/2150 100.00

19/161 7.85 20/48

10/189 7.28

29/252 9.06

11/111 3.64

Weight

224

5.10

3.35

2.83

2.27

5.94

5.34

2.41

3.57

3.28

2.26

6.33

6.96


4.93 14/281 6.76

1 2 3 4 5 6		
7 8 9	Study ID	Events, Event OR (95% CI) Bicarbonate Saline
9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 45 46 47 48 49 50 51 52	merten (2004) Ozcan (2007) Masuda (2007) REINEDIAL (2007) Adolph (2008) Brar (2008) Maioli (2009) Castini (2010) Vasheghani (2009) Castini (2010) Vasheghani (2010) Vasheghani (2010) Vasheghani (2010) Vasheghani (2011) PREVENT (2011) Ueda (2012) Gomes (2012) Hafiz (2012) Kristeller (2013) Boucek (2013) Kooiman (2014) Overall (I-squared = 48.4%, p = 0.008)	
53 54		

Page 30 of 35

BMJ Open: first published as 10.1136/bmjopen-2014-006989 on 17 March 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES)

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies



The forest plot of odds ratios of the requirement for dialysis 173x126mm (300 x 300 DPI)


1		
2		
3		
4		
5		
6 7		
8		
9	Study	Events, Events,
10	ID	OR (95% CI) Bicarbonate Saline
11		
12	Masuda (2007) 🔹	- 0.18 (0.01, 3.92) 0/30 2/29
13	Brar (2008)	1.02 (0.20, 5.11) 3/175 3/178
14	Maioli (2008)	1.35 (0.30, 6.09) 4/250 3/252
15	Ueda (2011)	- 0.62 (0.10, 4.01) 2/30 3/29
16	Gomes (2012)	0.85 (0.28, 2.58) 6/151 7/150
17	Kristeller (2013)	0.11 (0.01, 2.13) 0/44 4/48
18	Tamura (2009)	(Excluded) 0/72 0/72
19	Vasheghani(2) (2010)	(Excluded) 0/36 0/36
20 21	Motohiro (2011)	(Excluded) 0/78 0/77
21	PREVENT (2011)	(Excluded) 0/193 0/189
23	Hafiz (2012)	(Excluded) 0/159 0/161
24	Boucek (2013)	(Excluded) 0/61 0/59
25	Overall (I-squared = 0.0%, p = 0.650)	0.69 (0.36, 1.32) 15/1279 22/1280
26		
27	i	10
28	1 1	10
29		
30	The forest plot of odd	ls ratios of the mortality
31 32	173x121mm ((300 x 300 DPI)
33		
34		
35		
36		
37		
38		
39		
40		
41 42		
42 43		
44		
45		
46		
47		
48		
49		
50		
51		
52		
53		
54 55		
55 56		
56 57		
57 58		
50		
59 60		
59 60		
	For peer review only - http://bmjope	n.bmj.com/site/about/guidelines.xhtml

Page 32 of 35

BMJ Open: first published as 10.1136/bmjopen-2014-006989 on 17 March 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES)


Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies


BMJ Open



The influence of an individual study on the overall estimates $152 \times 107 \text{mm}$ (300 x 300 DPI)

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml





Funnel plot with pseudo 95% confidence limits 173x126mm (300 x 300 DPI)



PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported
TITLE	<u> </u>		
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT	<u>-</u>		
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2-3
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4-5
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	5
METHODS	-		
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	NA
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	6
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	6
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	6
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	6-7
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	6
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	7
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	7
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	7
	•	Pondo representation of the second	•

PRISMA 2009 Checklist

Additional analyses16Descr whichRESULTS516Descr whichStudy selection17Give r each sStudy characteristics18For each sStudy characteristics19PreseResults of bias within studies19PreseResults of individual studies20For al interverSynthesis of results21PreseAdditional analysis22PreseAdditional analysis23Give rSummary of evidence24Summ key grLimitations25Discus identifConclusions26ProvidFunding27Descr	fy any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective ing within studies). ibe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating were pre-specified.	7 7-8
whichRESULTSStudy selection17Give r each sStudy characteristics18For each sStudy characteristics18For each sRisk of bias within studies19PreseResults of individual studies20For al interverSynthesis of results21PreseRisk of bias across studies22PreseAdditional analysis23Give rDISCUSSIONJJSummary of evidence24Summ key grLimitations25Discus 		7-8
Study selection17Give r each sStudy characteristics18For each sRisk of bias within studies19PreseResults of individual studies20For al interverSynthesis of results21PreseRisk of bias across studies22PreseAdditional analysis23Give rDISCUSSION24Summary of evidenceLimitations25DiscusConclusions26ProvidFUNDING27DescrFrom:Moher D, Liberati A, Tetzlaff J, Altman DG, doi: 10.1371/journal.pmed1000097Altman DG, doi: 10.1371/journal.pmed1000097		
Study characteristics18For each second provideRisk of bias within studies19PreseResults of individual studies20For al interverseSynthesis of results21PreseRisk of bias across studies22PreseAdditional analysis23Give reseDISCUSSION24Summary of evidence24Summary of evidence24Summary of evidenceLimitations25DiscussionFUNDING27DescrFrom:Moher D, Liberati A, Tetzlaff J, Altman DG, doi:10.1371/journal.pmed1000097Altman DG, doi:10.1371/journal.pmed1000097		
ProvidRisk of bias within studies19Results of individual studies20Results of individual studies20Synthesis of results21PreseRisk of bias across studies22Additional analysis23Give rDISCUSSIONSummary of evidence24Limitations25Discusions26FUNDINGFunding27Descr systerFrom:Moher D, Liberati A, Tetzlaff J, Altman DG, doi:10.1371/journal.pmed1000097	numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at stage, ideally with a flow diagram.	Figure1
Results of individual studies20For al interverSynthesis of results21PreseRisk of bias across studies22PreseAdditional analysis23Give rDISCUSSION3Give rSummary of evidence24Summ key grLimitations25DiscustionConclusions26ProvidFUNDING27Descr systerFrom:Moher D, Liberati A, Tetzlaff J, Altman DG, TopolariaConclusion	ach study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and the citations.	Table1
Synthesis of results21PreseSynthesis of results21PreseRisk of bias across studies22PreseAdditional analysis23Give rDISCUSSION23Give rSummary of evidence24Summ key grLimitations25Discus identifConclusions26ProvidFUNDING27Descr systerFrom:Moher D, Liberati A, Tetzlaff J, Altman DG, Total 10, 1371/journal.pmed1000097	nt data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	Fig2/3a/3b
Risk of bias across studies22PreseAdditional analysis23Give rAdditional analysis23Give rDISCUSSION23Summary of evidenceSummary of evidence24Summ key grLimitations25DiscusidentifConclusions26ProvidFUNDING27Descr systerFrom:Moher D, Liberati A, Tetzlaff J, Altman DG, doi:10.1371/journal.pmed1000097	l outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each ention group (b) effect estimates and confidence intervals, ideally with a forest plot.	8-10Figure2 /3a/3b
Additional analysis 23 Give r Additional analysis 23 Give r DISCUSSION 24 Summary Summary of evidence 24 Summary Limitations 25 Discussidentif Conclusions 26 Provid FUNDING 27 Descr From: Moher D, Liberati A, Tetzlaff J, Altman DG, Totici J, 1371/journal.pmed1000097	nt results of each meta-analysis done, including confidence intervals and measures of consistency.	8-10Figure2 /3a/3b
DISCUSSION Summary of evidence 24 Summary of evidence Limitations 25 Discussion Conclusions 26 Providence FUNDING 27 Descr From: Moher D, Liberati A, Tetzlaff J, Altman DG, Todoi:10.1371/journal.pmed1000097 Summary of evidence	nt results of any assessment of risk of bias across studies (see Item 15).	9
Summary of evidence24Summ key grLimitations25Discus identifConclusions26ProvidFUNDING27Descr systerFrom:Moher D, Liberati A, Tetzlaff J, Altman DG, Topical pmed1000097	esults of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	10Figure 4 /Table3
Limitations 25 Discus identif Conclusions 26 Provid FUNDING 27 Descr From: Moher D, Liberati A, Tetzlaff J, Altman DG, 7 doi:10.1371/journal.pmed1000097		
identif Conclusions 26 FUNDING Funding 27 From: Moher D, Liberati A, Tetzlaff J, Altman DG, Topic 10, 1371/journal.pmed1000097	narize the main findings including the strength of evidence for each main outcome; consider their relevance to oups (e.g., healthcare providers, users, and policy makers).	10-13
FUNDING Funding 27 Descr Syster From: Moher D, Liberati A, Tetzlaff J, Altman DG, T doi:10.1371/journal.pmed1000097	ss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of ied research, reporting bias).	13-14
Funding 27 Descr system <i>From:</i> Moher D, Liberati A, Tetzlaff J, Altman DG, ⁻ doi:10.1371/journal.pmed1000097	le a general interpretation of the results in the context of other evidence, and implications for future research.	14
<i>From:</i> Moher D, Liberati A, Tetzlaff J, Altman DG, doi:10.1371/journal.pmed1000097		
dol. 10. 137 1/10umal.pmed 1000097	ibe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the natic review.	14
dol. 10. 137 1/10umal.pmed 1000097	The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med	6(6): e1000097
	For more information, visit: www.prisma-statement.org.	
2	Page 2 of 2	
iechnologies.		

BMJ Open